A DCLK1 protein degradation targeted chimera and its application

By designing DCLK1 protein degradation target chimera, using E3 ubiquitination ligase ligand to bind to target protein ligand, the problem of poor selectivity of protein kinase inhibitors is solved, and efficient degradation and anti-inflammatory effects on DCLK1 protein are achieved.

CN116375713BActive Publication Date: 2024-11-19THE NAVAL MEDICAL UNIV OF PLA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310209418.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-07
Publication Date
2024-11-19
Estimated Expiration
2043-03-07

Smart Images

  • Figure CN116375713B_ABST
    Figure CN116375713B_ABST
Patent Text Reader

Abstract

The present invention discloses a compound or a pharmaceutically acceptable salt thereof, the general structural formula of which is shown as follows: #imgabs0# The compound of the present invention exhibits good DCLK1 protein degradation activity. The DCLK1 protein degradation activity test results show that compounds P‑11, P‑12 and P‑14 with pomalidomide as the E3 ligase ligand have good degradation activity and are superior to the compound with VHL as the E3 ligase ligand.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a DCLK1 protein degradation targeting chimera and application thereof. Background Art

[0002] From the history of drug development, we can see that the focus of drug research and development has always been to exert therapeutic effects by blocking receptors or regulating protein binding sites. However, this mode of drug action usually requires high doses of drugs to maintain a high target occupancy, and may cause side effects due to off-target effects. Kinase inhibitors also have limitations in this mode of action. To solve this problem, protein degradation targeting chimeras (PROTACs) technology came into being. It uses the cell's own degradation mechanism to degrade target proteins, which can solve the defect of low selectivity of kinase inhibitors.

[0003] PROTAC molecules generally include two key domains: a specific domain that binds to the target protein (protein of interest, POI) and a domain that binds to the E3 ubiquitin ligase. The two are connected by a specific linker to induce ubiquitination of POI and degrade it through the proteasome pathway. Importantly, PROTAC molecules can still be recycled after POI ubiquitination and participate in new reactions. From a pharmacodynamic point of view, this catalytic degradation method is more meaningful than increasing the occupancy of the target protein. In addition, the action time of PROTAC molecules varies depending on the stability of PROTAC molecules in cells and the rate of resynthesis of POI. As long as there is a small molecule ligand with appropriate affinity for POI and the target protein and E3 ligase can be placed in a suitable spatial position to form a target protein-PROTAC-E3 ligase ternary complex, PROTAC molecules can theoretically target and degrade any type of protein.

[0004] At present, common E3 ligase ligands include CRBN, VHL, MDM2, clAP1, KEAP1 and RNF114, among which CRBN and VHL are the most commonly used. Different E3 ligases have diverse distribution in tissues, affinity with target proteins, and selectivity, which has an important impact on the safety, drugability, and efficacy of PROTAC. Therefore, it is necessary to guide the synthesis of PROTAC through reasonable medicinal chemistry and pharmacology.

[0005] After Gleevec was launched as the first protein kinase inhibitor in 2001, protein kinase inhibitors have received extensive attention and research, and currently 48 protein kinase inhibitors have been launched. However, the selectivity of protein kinase inhibitors is poor, mainly because one-third of protein kinases may be phosphorylated, and the binding domains of most kinases are very similar, making it very difficult to achieve selective inhibition. In addition, the "off-target effect" of kinase inhibitors often causes toxic side effects in clinical practice, so improving the selectivity of kinase inhibitors and reducing their toxicity are of great significance to the optimization of kinase drugs.

[0006] Since PROTAC needs to place the target protein and E3 ligase in a suitable spatial position to form a stable target protein-PROTAC-E3 ligase ternary complex, and there are suitable ubiquitination sites (such as lysine) on the surface of the target protein, even if the selectivity of the kinase inhibitor is poor, the selectivity can be greatly improved after being designed into PROTAC. Therefore, PROTAC technology is one of the important strategies to improve selectivity.

[0007] Doublecortin-like kinase 1 (DCLK1) is a microtubule-associated serine / threonine kinase that belongs to the calcium / calmodulin-dependent protein kinases (CaMK) family in structure and is mainly expressed in the cytoplasm. DCLK1 is composed of 729 amino acids and is divided into three parts: the DCX domain, the PEST sequence, and the kinase domain. Its N-terminal region has two microtubule-binding domains (DCX1 and DCX2, respectively) to drive microtubule-related functions; the C-terminal region contains a serine / threonine kinase domain that is highly similar to the kinase domain of calcium / calmodulin-dependent protein 1 (CaMK 1).

[0008] DCLK1 has many biological functions. Currently, research on it as a drug target is mainly focused on anti-tumor aspects, but no significant progress has been made. Recent studies have confirmed that DCLK1 is closely related to inflammation. Therefore, it is speculated that DCLK1 is very likely to be a potential anti-inflammatory drug target. Summary of the invention

[0009] The first object of the present invention is to provide a compound that can be used to prepare a DCLK1 protein degradation targeting chimera.

[0010] The second object of the present invention is to provide a use of the compound in preparing a DCLK1 protein degradation targeted chimera.

[0011] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0012] The first aspect of the present invention provides a compound or a pharmaceutically acceptable salt thereof, the general structural formula of which is shown below:

[0013]

[0014] Wherein, X is selected from one of the following structures: a bond,

[0015]

[0016] m is a positive integer selected from 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7);

[0017] n is a positive integer selected from 1 to 10 (e.g., 1, 2, 3, 4, 5);

[0018] r is a positive integer selected from 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7);

[0019] p is a positive integer selected from 1 to 10 (e.g., 1, 2, 3, 4);

[0020] q is a positive integer selected from 1 to 10 (e.g., 1, 2, 3);

[0021] s is a positive integer selected from 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7);

[0022] R is selected from one of the following structures:

[0023]

[0024] R1 is selected from hydrogen and methyl.

[0025] The pharmaceutically acceptable salt is an acid addition salt formed by the above compound and the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, lactic acid, citric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, tartaric acid, pyruvic acid, acetic acid, maleic acid, succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid.

[0026] The compound is selected from one of the following structures:

[0027]

[0028]

[0029]

[0030] The second aspect of the present invention provides an application of the compound or a pharmaceutically acceptable salt thereof in the preparation of a DCLK1 protein degradation targeted chimera, wherein the DCLK1 protein targeted degradation chimera molecule consists of three parts, an E3 ligase ligand (VHL ligand, pomalidomide ligand and lenalidomide ligand), a target protein ligand and a linker. The E3 ligase ligand is responsible for the specific recruitment of the E3 ligase. The target protein ligand is used to target and capture the target protein. Linker is used to combine the two ligands to form a stable ternary complex. Therefore, the PROTAC molecule can recruit the E3 ligase to the vicinity of the target protein, label the target protein with a "ubiquitin" tag, and the protein labeled with a ubiquitin tag on the cell will be sent to the proteasome for degradation. In this way, the PROTAC molecule can specifically promote the degradation of pathogenic proteins, thereby achieving the purpose of treating the disease.

[0031] The third aspect of the present invention provides a use of the compound or a pharmaceutically acceptable salt thereof in the preparation of an anti-inflammatory drug.

[0032] The inflammation in the anti-inflammatory drug refers to inflammation related to DCLK1 expression, and the inflammation related to DCLK1 expression may be sepsis, septicemia, acute lung injury or diabetic complications.

[0033] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:

[0034] The compounds of the present invention exhibit good DCLK1 protein degradation activity. The DCLK1 protein degradation activity test results show that at a single concentration of 10 μM, in the DCLK1 protein degradation targeting chimera (compounds P-1 to P-6, P-9) with VHL as the E3 ligase ligand, the carbon-oxygen heterochain and the compounds P-1 and P-9 containing three carbon atoms of the fatty chain have certain degradation activity, and in the compounds P-2 to P-6 containing 4-8 carbon atoms of the fatty chain, as the chain length increases, the degradation activity gradually weakens; a time-dependent experiment is performed on the compound P-9 with the best anti-inflammatory activity, and the degradation activity is gradually weakened from 0.5h to 1h after administration. 3h, the degradation rate of DCLK1 gradually increased with time, and the degradation effect no longer changed after 3h, indicating that the PROTAC molecule can achieve maximum degradation at 3h, so the subsequent drug action time is 3h; for some DCLK1 protein degradation targeting chimeras with pomalidomide as E3 ligase ligand, 10μM single concentration degradation activity screening was carried out, and it was found that compounds P-11, P-12 and P-14 had good degradation activity, which corresponded to DCLK1 protein degradation targeting chimeras without linker, containing 2 carbon atoms of fat linker and containing 5 carbon atoms of fat linker. By comparing the degradation activities of two different types of E3 ligase ligands, it was found that the PROTAC molecule with CRBN as the E3 ligase ligand had better degradation activity. The compound P-14 with better degradation activity was selected for concentration-dependent degradation experiments, and it was found that in the three concentrations of 0.1-10μM, as the concentration increased, the degradation efficiency decreased instead. The reason for the analysis may be that the PROTAC molecule produced a HOOK effect at high concentrations, and the specific degradation efficiency needs to be further verified.

[0035] The compound of the present invention is the first reported DCLK1 protein degradation targeting chimera and has further development and research value. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 It is a schematic diagram of the test results of the in vitro anti-inflammatory activity of the compounds of the present invention.

[0037] Figure 2 This is a schematic diagram of the degradation activity test results of DCLK1-PROTAC. DETAILED DESCRIPTION

[0038] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0039] In the present invention, EDCI is 1-ethyl-3 (3-dimethylpropylamine) carbodiimide, HOBT is 1-hydroxybenzotriazole, DIPEA is N,N-diisopropylethylamine, DCM is dichloromethane, MeOH is methanol, and THF is tetrahydrofuran.

[0040] The structure of LRRK2-IN-1, a DCLK1 inhibitor with excellent activity, is shown below:

[0041]

[0042] Example 1

[0043] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(piperidin-4-yl)benzamide (8 g)

[0044]

[0045] Reagents and conditions: a) SOCl2, MeOH, 60℃, 2h, yield 92%; b) DIPEA, 1,4-dioxane, 50℃, 5h, yield 82%; c) Fe, AcOH, 60℃, overnight, yield 93%; d) Mel, NaH, DMF, 0℃, 5h, yield 80%; e) DCM, EDCI, HOBT, DIPEA, rt, overnight, yield 84.3%; f) X-Phos, Pd2(dba)3, 1,4-dioxane, 100℃, 5h, yield 37.1%; g) DCM, TFA, 4h, yield 39%.

[0046] Step a: Synthesis of methyl 2-(methylamino)benzoate (2)

[0047] Compound 1 (2-(methylamino)benzoic acid) (5.00 g, 33.08 mmol) was placed in a 250 mL eggplant-shaped bottle, methanol (100 mL) was added to dissolve, dichlorothionyl (19.70 g, 165.38 mmol) was slowly added dropwise under stirring, and the mixture was reacted at 60° C. for 2 h. The reaction was complete by TLC detection, and the reaction solution was poured into ice water (500 mL) and stirred for 5 min. A large amount of white solid precipitated, which was filtered and dried without further purification to obtain compound 2 (white solid, 5 g, yield: 92%). 1H NMR(300MHz, DMSO-d6)δ:7.73(s,1H),7.40(s,1H),6.93(s,1H),6.82(s,1H),3.95(s,3H),2.64(s,3H).

[0048] Step b: Synthesis of methyl 2-((2-chloro-5-nitropyrimidin-4-yl)(methyl)amino)benzoate (4)

[0049] Compound 2 (1.00 g, 6.06 mmol) and compound 3 (2,4-dichloro-5-nitropyrimidine, 1.40 g, 7.26 mmol) were dissolved in 1,4-dioxane (50 mL), and DIPEA (1.60 g, 12.12 mmol) was slowly added dropwise under stirring, and stirred at 50°C for more than 5 h. After the reaction was complete, the reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by silica gel column chromatography (hexane: EtOAc = 15: 1-10: 1) to obtain compound 4 (yellow solid, 1.6 g, yield: 82%). 1 H NMR(300MHz,DMSO-d6)δ:8.72(s,1H),7.93(dd,J=8.3,1.6Hz,1H),7.65-7.76(m ,1H),7.46-7.59(m,2H),4.03-4.26(m,2H),3.47(s,3H),1.19(t,J=7.1Hz,3H).

[0050] Step c: Synthesis of 2-chloro-11-methyl-5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one (5)

[0051] Compound 4 (1.00 g, 3.10 mmol) was dissolved in 20 mL of acetic acid, and iron powder (0.87 g, 15.49 mmol) and DIPEA (0.80 g, 6.20 mmol) were added in sequence under stirring, and stirred at 60° C. overnight. After the reaction was complete by TLC detection, the remaining iron powder was filtered, and the filtrate was added to 500 mL of ice water, and a large amount of white solid precipitated. The filter cake was dried at 50° C. and directly carried out to the next step without purification to obtain compound 5 (white solid, 0.7 g, yield: 93%). 1 H NMR (300MHz, DMSO-d6) δ: 10.48 (s, 1H), 8.15 (s, 1H), 7.72 (d, J = 7.5Hz, 1H), 7. 59(t,J=7.5Hz,1H), 7.28(d,J=8.0Hz,1H), 7.22(t,J=7.5Hz,1H), 3.34(s,3H).

[0052] Step d: Synthesis of 2-chloro-5,11-dimethyl-5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one (6)

[0053] Compound 5 (1.00 g, 3.84 mmol) was dissolved in dry DMF (20 mL), and NaH (120.00 mg, 4.60 mmol) was added in batches at -10 ° C. After the reaction for 0.5 h, iodomethane (660.00 mg, 4.60 mmol) was slowly added dropwise, and then the reaction was transferred to room temperature and stirred for 4 h. After the raw materials were completely reacted, the reaction solution was poured into ice water (400 mL) and stirred for 5 min. A large amount of white solid precipitated, which was filtered and the filter cake was dried at 50 ° C to constant weight without further purification to obtain compound 6 (white solid, 0.8 g, yield 80%). 1 H NMR (300MHz, DMSO-d6) δ: 8.60 (s, 1H), 7.71 (dd, J = 7.8, 1.5Hz, 1H), 7.51-7.62 ( m, 1H), 7.29 (d, J = 8.3Hz, 1H), 7.22 (t, J = 7.7Hz, 1H), 3.42 (s, 3H), 3.34 (s, 3H).

[0054] Step e: Synthesis of tert-butyl 4-(4-amino-3-methoxybenzamido)piperidine-1-carboxylate (9)

[0055] Compound 7 (2.00 g, 12.00 mmol), compound 8 (2.88 g, 14.36 mmol), EDCI (2.75 g, 14.36 mmol), and HOBT (1.94 g, 14.36 mmol) were weighed into a 100 mL round-bottom flask, and dry dichloromethane (40 mL) was added to fully dissolve. DIPEA (5.93 mL, 35.89 mmol) was slowly added dropwise while stirring. The reaction was stirred at room temperature overnight and monitored by TLC spot plate (developing solvent conditions, DCM:MeOH=100:10). The reaction was complete. The reaction solution was poured into a 250 mL separatory funnel, 100 mL of water was added, 30 mL of dichloromethane was added, the mixture was shaken thoroughly, and the liquid was allowed to stand until it was completely separated. The lower layer of liquid was taken into a 250 mL round-bottom flask, and the extraction was repeated 4-5 times. The extracts were combined and spin-dried, and then mixed with the sample for column chromatography. The eluent was DCM:MeOH = 100:1, and the polarity was gradually increased to DCM:MeOH = 100:5. The eluate was concentrated under reduced pressure to obtain compound 9 (light yellow solid, 3.52 g, yield 84.3%).

[0056] Step f: Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(piperidin-4-yl)benzamide (8 g)

[0057] Compound 6 (250 mg, 0.90 mmol), compound 9 (344 mg, 0.98 mmol), X-Phos (39 mg, 0.08 mmol), Pd2(dba)3 (74 mg, 0.08 mmol) and potassium carbonate (375 mg, 2.68 mmol) were weighed into a 100 mL round-bottom flask, and dry 1,4-Dioxane (30 mL) was added to fully dissolve. The mixture was evacuated under N2 protection and refluxed at 106 °C for 4.5 h. During the entire reaction process, contact with air and water was avoided as much as possible. The spherical condenser used should be fully dried in an oven in advance. The reaction was completed by TLC spot plate monitoring (developing agent conditions, DCM:MeOH=100:10). The reaction solution was filtered with a triangular funnel to remove inorganic salt solids as much as possible, and the filter residue was rinsed with a little methanol for 3 times. The filtrate was poured into a 100 mL separatory funnel, 40 mL of water was added, and then 15 mL of ethyl acetate was added. The mixture was shaken thoroughly and allowed to stand until the liquid was completely separated. The upper layer of liquid was taken into a 100 mL round-bottom flask, and the extraction was repeated 4-5 times. The extracts were combined and spin-dried, and then mixed with samples for column chromatography. The eluent was PE:EA=50:1, and the polarity was gradually increased to: PE:EA=73:27. The eluent was concentrated under reduced pressure to obtain the product 10 (yellow solid, 195 mg, yield 37.1%).

[0058] Compound 10 (195 mg, 0.33 mmol) was weighed into a 50 mL round-bottom flask, and dry dichloromethane (8 mL) was added to fully dissolve. Trifluoroacetic acid (2 mL) was added while stirring, and the reaction was stirred at room temperature overnight. TLC spot plate monitoring (developing solvent conditions, DCM: MeOH = 100: 10) showed that the reaction was complete. The reaction solution was spin-dried, a small amount of methanol was added to fully dissolve and then spin-dried again, and repeated 5-6 times. Finally, after fully dissolving with dichloromethane, the sample was directly mixed with column chromatography, eluent: DCM: MeOH = 100: 1, and the polarity was gradually increased to DCM: MeOH = 100: 7. The eluent was concentrated under reduced pressure to obtain 8 g of the product (white solid, 63 mg, yield 39%). 1H NMR (600MHz, CDCl3) δ: 8.51 (d, J=8.4Hz, 1H), 8.15 (s, 1H), 7.78-7.86 (m, 2H), 7.45 (d, J= 1.6Hz,1H),7.38-7.43(m,1H),7.31(dd,J=8.4,1.6Hz,1H),7.12(t,J=7.8Hz,1H),7.07( d,J=8.4Hz,1H),6.06-6.17(m,1H),4.02-4.13(m,1H),3.96(s,3H),3.48(s,3H),3.41(s ,3H),2.77(t,J=12.1Hz,1H),2.1-2.3(m,2H),2.04(d,J=11.1Hz,2H),1.40-1.48(m,2H); 13 C NMR(150MHz, CDCl3)δ:168.22,166.35,163.67,155.38,151.30,149.28,147.47,132.46,132.35,132.28,1 27.53,126.49,123.84,122.04,118.97,117.39,116.45,109.31,56.00,47.33,45.44,38.24,35.96,33.48.

[0059] Example 2

[0060] Synthesis of (2S,4R)-1-((S)-2-(3-(4-(4-(5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl)[5,4-b][1,4]diaza-2-(yl)amino)-3-methoxybenzamido)piperidin-1-yl)-3-oxopropanamido)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-1)

[0061]

[0062] Reagents and conditions: a) EDCI, HOBT, DIPEA, DCM, rt, 1 h, yield 80-90%; b) MeOH, THF, H2O, LiOH, rt, 50°C, 5 h, yield 80-87%; c) EDCI, HOBT, DIPEA, DCM, rt, 2 h, yield 50-65%.

[0063] Step a: Synthesis of compound 12

[0064] Compound 8g (0.70g, 1.44mmol) and compound 11 (0.20g, 1.72mmol) were dissolved in 20mL dry DCM, and EDCI (0.30g, 1.72mmol), HOBT (0.20g, 1.72mmol), and DIPEA (0.40g, 3.59mmol) were added in sequence, and stirred at room temperature for 2h. After the reaction was completed as monitored by TLC, the reaction solution was washed 3 times with 60mL saturated sodium chloride solution, and the organic layer was concentrated under reduced pressure, and separated and purified by silica gel column chromatography (hexane / EtOAc=3:1-1:1) to obtain compound 12 (white solid, 698mg, yield 85%). 1 H NMR (300MHz, CDCl3) δ: 8.50 (d, J = 8.3Hz, 1H), 8.14 (s, 1H), 7.84 (dd, J = 7.8, 1.5Hz, 1H), 7.40-7.45 (m, 2H), 7. 30(dd,J=8.4,1.5Hz,1H),7.14(t,J=7.4Hz,1H),7.08(d,J=8.3Hz,1H),6.08(d,J=7.8Hz,1H),4.62(d,J=13. 9Hz,1H),4.18-4.26(m,1H),3.97(s,3H),3.72-3.77(m,1H),3.70(q,J=7.1Hz,1H),3.49(s,3H),3.42(s,3H) ,3.21-3.26(m,1H),2.78-2.85(m,1H),2.11-2.16(m,1H),2.03-2.08(m,1H),1.48-1.57(m,4H),1.46(s,3H).

[0065] Step b: Synthesis of (P-1)

[0066] Compound 12 (500 mg, 0.85 mmol) was dissolved in a mixed solvent (100 mL) of THF:MeOH:H2O=3:2:1, and LiOH (96 mg, 4.25 mmol) was added in batches. The reaction was allowed to react for 5 h at room temperature. TLC detected that the reaction was complete. The reaction solution was distilled under reduced pressure to remove the organic solvent, and then transferred to an ice bath. The pH was adjusted to neutral with 1 mol / L HCl. A large amount of white solid precipitated, which was filtered and dried without further purification to obtain 400 mg of a crude product of compound 13 with a yield of 87%.

[0067] Compound 13 (100 mg, 0.17 mmol) and VHL ligand 14 (133.2 mg, 0.26 mmol) were dissolved in dry DCM (20 mL), and EDCI (58 mg, 0.26 mmol), HOBT (42 mg, 0.26 mmol), and DIPEA (77 mg, 0.52 mmol) were added in sequence, and the mixture was reacted at room temperature for 2 h. After the reaction was completed by TLC monitoring, the reaction solution was washed three times with saturated sodium chloride solution (150 mL×3), dried over anhydrous sodium sulfate, and separated and purified by silica gel column chromatography (DCM:MeOH=100:1-100:3) to obtain compound P-1 (white solid, 300 mg, yield 37%). 1 H NMR (600MHz, CDCl3) δ: 8.64 (d, J=7.5Hz, 1H), 8.50 (dd, J=8.5, 4.5Hz, 1H), 8.37 (d ,J=8.2Hz,1H),8.13(s,1H),7.81-7.86(m,2H),7.38-7.50(m,3H),7.29-7.36(m, 4H),7.10-7.15(m,1H),7.06(d,J=8.4Hz,1H),6.94(dd,J=102.9,8.0Hz,1H),5.0 0-5.07(m,1H),4.73(t,J=8.4Hz,1H),4.63(t,J=8.0Hz,1H),4.54-4.61(m,2H),4 .47(s,1H),4.13-4.23(m,1H),4.07(dd,J=31.0,13.0Hz,1H),3.90-3.95(m,3H), 3.76-3.89(m,1H),3.56-3.63(m,1H),3.46-3.49(m,3H),3.39(s,3H),3.31-3.37 (m.1H),3.11-3.18(m,1H),2.68-2.76(m,2H),2.46-2.50(m,3H),2.22-2.32(m,1 H),1.91-2.15(m,3H),1.45(d,J=6.9Hz,3H),1.40(d,J=6.1Hz,2H),1.07(s,9H); 13C NMR(150MHz, CDCl3)δ:172.63,171.47,169.59,168.86,168.43,168.05,167.73,167.32,165.03,156.66,152.58,151.69,150. 57,149.73,148.66,144.93,144.78,133.88,133.68,133.00,132.01,130.80,128.41,128.20,127.75,125.21,123.47,121.14, 118.81,117.77,110.68,71.50,60.19,59.98,59.70,59.44,58.38,57.36,55.49,50.23,48.31,46.75,43.67,42.85,42.01,41. 03,39.62,37.68,37.45,37.29,36.77,36.41,33.59,32.99,27.92,23.68,19.94,18.68,17.42,13.46; HRMS(ESI,positive)m / z calcd for C 52 H 62 N 11 O8S[M+H] + :1000.4498; found 1000.4487.

[0068] Example 3

[0069] Synthesis of (2R,4S)-1-((R)-2-(4-(4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl][5,4-b][1,4]diaza-2-(amino)-3-methoxybenzamido)piperidin-1-yl)-4-oxavaleramido)-3,3-dimethylbutyryl)-4-hydroxy-N-((R)-1-(4-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-2)

[0070] Step a: Synthesis of compound 12-1

[0071]

[0072] Compound 11 was replaced with compound 4-methoxy-4-oxobutanoic acid, and the synthesis method was referred to step a in Example 2. 600 mg of white solid, yield 86%. 1H NMR (300MHz, CDCl3) δ: 8.51 (d, J=8.3Hz, 1H), 8.15 (s, 1H), 7.85 (dd, J=7.8, 1.6Hz, 1H), 7.39-7.46 (m, 2H), 7. 29(dd,J=8.3,1.6Hz,1H),7.15(t,J=7.6Hz,1H),7.10(d,J=8.4Hz,1H),6.09(d,J=7.9Hz,1H),4.61(d,J=14. 0Hz,1H),4.19-4.27(m,1H),3.98(s,3H),3.70-3.78(m,1H),3.71(q,J=7.2Hz,1H),3.50(s,3H),3.44(s,3H) ,3.20-3.28(m,1H),2.79-2.86(m,1H),2.09-2.17(m,1H),2.02-2.09(m,1H),1.49-1.58(m,6H),1.46(s,3H).

[0073] Step b: Synthesis of compound P-2

[0074]

[0075] The synthesis method is as in step b of Example 2. 100 mg of white solid, yield 30%. 1H NMR(600MHz,CDCl3)δ:8.67(s,1H),8.51(d,J=8.4Hz,1H),8.16(s,1H),7.86(d,J=4.5Hz,1H),7.84(dd,J=7.9,1.7Hz,1H),7.64-7.69(m,1H),7.46-7.50(m,1H),7.32-7.45(m,6H),7.13(t,J=7.5Hz,1H),7.09(t,J=8.4Hz,1H),6.86-6.94(m,1H),5.01-5.12(m,1H),4.72-4.81(m,1H),4.49-4.60(m,2H),4.46(s,1H),4.18-4.27(m,1H),4.08(t,J=12.1Hz,1H),3.94(s,3H),3.84-3.91(m,1H),3.57-3.61(m,1H),3.49(s,3H),3.41(s,3H),3.10-3.16(m,1H),2.63-2.75(m,3H),2.50(s,3H),2.44-2.48(m,1H),2.35-2.42(m,1H),2.10-2.17(m,1H),2.02-2.08(m,1H),1.47(d,J=6.7Hz,3H),1.23-1.34(m,4H),1.06(s,9H); 13 C NMR(150MHz,CDCl3)δ:174.53,173.3,171.83,169.59,167.93,165.06,156.66,152.54,151.78,150.57,149.72,148.77,144.73,133.87,133.72,133.02,132.10,130.87,128.48,127.79,125.22,123.45,120.47,118.79,117.75,110.75,71.55,59.83,59.48,58.20,57.37,50.20,48.28,46.28,43.01,39.64,37.54,37.31,36.46,33.83,33.11,32.94,32.27,30.37,29.31,27.92,24.00,23.56,15.58,12.78;HRMS(ESI,positive)m / z calcd for C 53 H 64 N 11 O8S[M+H] + :1014.4655;found 1014.4554.

[0076] Example 4

[0077] Synthesis of (2S,4R)-1-((S)-2-(5-(4-(4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl][5,4-b][1,4]diazepin-2-yl)amino)-3-methoxybenzamido)piperidin-1-yl)-5-oxopentanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-3)

[0078] Step a: Synthesis of compound 12-2

[0079]

[0080] Compound 11 was replaced with 5-methoxy-5-oxopentanoic acid, and the synthesis method was referred to step a in Example 2. 500 mg of white solid, yield 80%. 1 H NMR(300MHz, CDCl3)δ:8.50(d,J=8.5Hz,1H),8.15(s,1H),7.95(s,1H),7.84(d,J=7.8Hz,1H),7.40-7.49(m,2H) ,7.29(d,J=8.6Hz,1H),7.14(t,J=7.7Hz,1H),7.07(d,J=8.3Hz,1H),6.03(d,J=7.7Hz,1H),4.60(d,J=13.6Hz,1 H),4.16-4.25(m,1H),3.97(s,3H),3.89(d,J=13.8Hz,1H),3.67(s,3H),3.49(s,3H),3.42(s,3H),3.19(t,J=11 .7Hz,1H),2.78(t,J=11.9.Hz,1H),2.38-2.43(m,4H),2.15-2.19(m,1H),2.03-2.08(m,1H),1.93-2.00(m,4H).

[0081] Step b: Synthesis of compound P-3

[0082]

[0083] The synthesis method is as in step b of Example 2. 106 mg of white solid, yield 36%. 11H NMR (600 MHz, CDCl3) δ: 8.68 (s, 1H), 8.53 (dd, J = 8.3, 5.0 Hz, 1H), 7.88 (s, 1H), 7.86 (dd, J = 7.9, 1.2 Hz, 1H), 7.48 (s, 1H), 7.32 - 7.47 (m, 6H), 7.15 (t, J = 7.4 Hz, 1H), 7.09 (d, J = 8.7 Hz, 1H), 6.67 - 6.91 (m, 1H), 6.51 - 6.61 (m, 1H), 5.01 - 5.13 (m, 1H), 4.73 (q, J = 7.9 Hz, 1H), 4.64 - 4.57 (m, 1H), 4.52 - 4.56 (m, 1H), 4.44 - 4.52 (m, 1H), 4.26 - 4.19 (m, 1H), 4.09 - 4.18 (m, 1H), 3.96 (s, 3H), 3.82 - 3.88 (m, 1H), 3.56 - 3.63 (m, 1H), 3.51 (s, 3H), 3.43 (s, 3H), 3.12 - 3.21 (m, 1H), 2.73 - 2.80 (m, 1H), 2.53 (s, 3H), 2.19 - 2.49 (m, 6H), 2.09 - 2.16 (m, 2H), 1.91 - 2.05 (m, 4H), 1.46 (d, J = 22.8 Hz, 3H), 1.08 (s, 9H); 13 13C NMR (150 MHz, CDCl3) δ: 174.72, 173.42, 172.33, 171.10, 169.56, 167.89, 163.91, 156.64, 152.51, 150.56, 149.83, 148.83, 14.68, 133.86, 132.20, 130.90, 127.78, 127.75, 120.71, 118.79, 117.81, 110.70, 71.43, 59.79, 59.39, 58.18, 57.38, 50.18, 48.47, 46.18, 42.43, 39.63, 37.34, 36.37, 34.22, 33.26, 27.98, 23.65, 17.46; HRMS (ESI, positive) m / z calcd for C 54 H 66 N 11 O8S [M + H] + : 1028.4211; found 1028.4836.

[0084] Example 5

[0085] Synthesis of (2S,4R)-1-((S)-2-(6-(4-(4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl][5,4-b][1,4]diaza-2-(amino)-3-methoxybenzamido)piperidin-1-yl)-6-oxohexanamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-4)

[0086] Step a: Synthesis of compound 12-3

[0087]

[0088] Compound 11 was replaced with compound 6-methoxy-6-oxohexanoic acid, and the synthesis method was referred to step a in Example 2. 400 mg of white solid, yield 83%. 1 H NMR(300MHz, CDCl3)δ:8.49(d,J=8.4Hz,1H),8.14(s,1H),7.93(s,1H),7.83(dd,J=7.8 ,1.5Hz,1H),7.44(d,J=1.7Hz,1H),7.39-7.43(m,1H),7.30(dd,J=8.4,1.6Hz,1H),7.13 (t,J=7.6Hz,1H),7.06(d,J=8.4Hz,1H),7.15(d,J=7.9Hz,1H),4.60(d,J=14.0Hz,1H),4 .16-4.25(m,1H),3.96(s,3H),3.85(d,J=13.7Hz,1H),3.64(s,3H),3.48(s,3H),3.41(s 3H),3.14-3.21(m,1H),2.72-2.80(m,1H),2.28-2.36(m,6H),2.12-2.18(m,1H),1.2-1.68(m,6H).

[0089] Step b: Synthesis of compound P-4

[0090]

[0091] The synthesis method is as in step b of Example 2. 110 mg of white solid, yield 36%. 11H NMR (600 MHz, CDCl3) δ: 8.68 (s, 1H), 8.51 (t, J = 7.3 Hz, 1H), 8.16 (s, 1H), 7.98 (s, 1H), 7.86 (dd, J = 7.6, 1.4 Hz, 1H), 7.34 - 7.59 (m, 9H), 7.15 (t, J = 7.6 Hz, 1H), 7.09 (d, J = 8.3 Hz, 1H), 6.46 - 6.62 (m, 2H), 5.02 - 5.13 (m, 1H), 4.70 - 4.79 (m, 2H), 4.48 (s, 1H), 4.21 (s, 1H), 4.08 (d, J = 11.1 Hz, 1H), 3.96 (s, 3H), 3.84 (d, J = 12.2 Hz, 1H), 3.56 - 3.63 (m, 1H), 3.50 (s, 3H), 3.43 (s, 3H), 3.17 (t, J = 12.5 Hz, 1H), 2.71 - 2.80 (m, 1H), 2.53 (s, 3H), 2.13 - 2.43 (m, 8H), 1.59 - 1.72 (m, 4H), 1.47 (d, J = 4.5 Hz, 3H), 1.06 (s, 9H); 13 13C NMR (150 MHz, CDCl3) δ: 174.72, 173.37, 172.67, 171.20, 169.48, 167.96, 165.21, 151.69, 149.97, 148.93, 144.63, 133.89, 132.63, 130.90, 127.80, 125.34, 123.42, 120.70, 118.86, 117.98, 110.73, 71.40, 59.91, 59.11, 58.29, 57.40, 50.18, 48.52, 46.10, 42.36, 39.69, 37.42, 37.23, 36.57, 34.12, 33.20, 27.92, 26.51, 25.87, 24.01, 23.63, 17.41; HRMS (ESI, positive) m / z calcd for C 55 H 68 N 11 O8S [M + H] + : 1042.4968; found 1042.4967.

[0092] Example 6

[0093] Synthesis of (2S,4R)-1-((S)-2-(7-(4-(4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl(amino)-3-methoxybenzamide)piperidin-1-yl)-7-oxoheptylamide)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-5)

[0094] Step a: Synthesis of compound 12-4

[0095]

[0096] Compound 11 was replaced with compound 7-methoxy-7-oxoheptanoic acid, and the synthesis method was referred to step a in Example 2. 600 mg of white solid, yield 86%. 1 H NMR(300MHz, DMSO-d6)δ:8.43(s,1H),8.32(d,J=8.4Hz,1H),8.22(d,J=8.0Hz,1H),8.13(s,1H),7.68(dd,J=7.6,1.5H z,1H),7.54(dd,J=8.4,1.5Hz,1H),7.47-7.52(m,2H),7.24(d,J=8.4Hz,1H),7.16(t,J=7.3Hz,1H),4.38(d,J=12.4Hz ,1H),4.00-4.07(m,1H),3.92(s,3H),3.89(s,1H),3.80(s,3H)3.39(s,3H),3.34(s,3H),3.09(t,J=12.4Hz,1H),2.64 (t,J=12.1Hz,1H),2.25-2.37(m,2H),2.13(t,J=7.1Hz,2H),1.76-1.88(m,2H),1.65-1.71(m,2H),1.34-1.51(m,2H).

[0097] Step b: Synthesis of compound P-5

[0098]

[0099] The synthesis method is as in step b of Example 2. 120 mg of white solid, yield 33%. 1H NMR(600MHz,CDCl3)δ:8.67(s,1H),8.50(t,J=7.8Hz,1H),8.15(d,J=1.5Hz,1H),7.87(s,1H),7.84(dd,J=8.0,1.5Hz,1H),7.49-7.53(m,1H),7.48(s,1H),7.34-7.43(m,6H),7.13(t,J=7.6Hz,1H),7.07(d,J=8.3Hz,1H),6.63-6.81(m,1H),6.43-6.60(m,1H),5.04-5.12(m,1H),4.67-4.75(m,1H),4.53-4.64(m,2H),4.49(s,1H),4.22(s,1H),4.02(dd,J=20.0,11.4Hz,1H),3.95(s,3H),3.85(d,J=12.9Hz,1H),3.58-3.63(m,1H),3.49(s,3H),3.41(s,3H),3.06-3.20(m,2H),2.68-2.76(m,1H),2.51(s,3H),2.22-2.42(m,4H),2.08-2.19(m,1H),1.57-1.65(m,4H),1.46(d,J=6.8Hz,3H),1.29-1.37(m,6H),1.03(s,9H); 13 C NMR(150MHz,CDCl3)δ:174.99,173.26,172.97,171.34,169.56,167.97,165.08,156.62,152.46,151.74,150.54,149.73,148.79,144.70,133.72,133.01,132.13,130.88,128.49,127.79,125.24,123.45,120.83,118.79,117.83,110.73,71.26,60.12,58.98,58.32,57.38,55.09,50.17,48.50,46.20,42.40,39.64,37.34,36.80,34.23,33.20,31.05,29.90,27.92,26.48,26.16,24.05,23.58,17.40;HRMS(ESI,positive)m / z calcd for C 56 H 70 N 11 O8S[M+H] + :1056.5124;found 1056.5131.

[0100] Example 7

[0101] Synthesis of (2S,4R)-1-((S)-2-(8-(4-(4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diaza-2-(amino)-3-methoxybenzamido)piperidin-1-yl)-8-oxooctylamino)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-6)

[0102] Step a: Synthesis of compound 12-5

[0103]

[0104] Compound 11 was replaced with compound 8-methoxy-8-oxooctanoic acid, and the synthesis method was referred to step a in Example 2. 400 mg of white solid, yield 80%. 1 H NMR (300MHz, CDCl3) δ: 8.49 (d, J = 8.2Hz, 1H), 8.14 (s, 1H), 7.88 (s, 1H), 7.82 (d, J = 7.5Hz, 1H), 7.44 (d, J = 1.4Hz, 1H), 7.40 ( t,J=7.3Hz,1H),7.32(dd,J=8.6,1.1Hz,1H),7.12(t,J=7.6Hz,1H),7.05(d,J=8.3Hz,1H),6.26(d,J=7.9Hz,1H),4.60(d,J= 13.0Hz,1H),4.15-4.23(m,1H),3.95(s,3H),3.86(d,J=14.2Hz,1H),3.62(s,3H),3.47(s,3H),3.40(s,3H),3.17(t,J=12.1 Hz,1H),2.71-2.80(m,1H),2.11-2.17(m,1H),1.98-2.03(m,1H),1.56-1.63(m,10H),1.42-1.44(m,2H),1.35-1.39(m,2H).

[0105] Step b: Synthesis of compound P-6

[0106]

[0107] The synthesis method is as in step b of Example 2. 39 mg of white solid, yield 28%. 1H NMR(600MHz,DMSO-d6)δ:8.67(s,1H),8.54(dd,J=8.4,5.1Hz,1H),8.18(d,J=1.8Hz,1H),7.84-7.87(m,2H),7.34-7.50(m,9H),7.15(t,J=7.2Hz,1H),7.08(d,J=8.1Hz,1H),6.47(dd,J=8.1,69.1Hz,1H),6.30(dd,J=8.6,31.0Hz,1H),5.06-5.11(m,1H),4.72(q,J=8.6Hz,1H),4.57-4.64(m,2H),4.50(s,1H),4.19-4.27(m,1H),4.03(t,J=11.2Hz,1H),3.98(s,3H),3.85-3.90(m,1H),3.65(s,1H),3.56-3.60(m,H),3.51(s,3H),3.43(s,3H),3.16-3.21(m,1H),2.72-7.78(m,1H),2.53(s,3H),2.29-2.40(m,2H),1.98-2.25(m,8H),1.59-1.64(m,4H),1.48(d,J=6.9Hz,1H),1.31-1.35(m,4H),1.03(d,J=3.2Hz,1H); 13 C NMR(150MHz,DMSO-d6)δ:175.05,173.40,173.04,171.19,169.57,167.91,165.06,156.70,152.62,151.66,150.60,149.86,148.78,144.58,133.84,133.74,132.94,132.25,130.91,128.45,127.84,127.80,125.24,123.52,120.66,118.76,117.77,110.70,71.86,71.27,59.98,58.88,58.19,57.39,50.19,48.50,46.16,42.32,39.63,37.62,37.32,36.60,34.45,34.38,33.26,30.01,29.87,27.89,26.55,26.42,23.60,17.46;HRMS(ESI,positive)m / zcalcd for C 57 H 72 N 11 O8S[M+H] +:1070.5281; found 1070.5285.

[0108] Example 8

[0109] Synthesis of (2S,4R)-1-((S)-2-(2-(2-(4-(4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-yl)amino)-3-methoxybenzamido)piperidin-1-yl)-2-oxoethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-7)

[0110]

[0111] Reagents and conditions: a) EDCI, HOBT, DIPEA, DCM, rt, 0.5h; b) EDCI, HOBT, DIPEA, DCM, rt, 1h, two steps yield 30-40%.

[0112] Step: Synthesis of compound P-7

[0113] Compound 8g (500 mg, 1.03 mmol) and compound 15 (165 mg, 1.23 mmol) were dissolved in dry DCM (20 mL), and EDCI (287 mg, 1.54 mmol), HOBT (209 mg, 1.54 mmol), and DIPEA (387 mg, 3.08 mmol) were added in sequence, and stirred at room temperature for 0.5 h. After the reaction was completed, the reaction solution was distilled under reduced pressure and purified by silica gel column chromatography (DCM: MeOH = 100: 1) to obtain compound 16. Then compound 16 (300 mg, 0.50 mmol), intermediate 8 (266 mg, 0.60 mmol), EDCI (133 mg, 0.70 mmol), HOBT (97 mg, 0.70 mmol) and DIPEA (258 mg, 2.00 mmol) were dissolved in dry DCM (20 mL) and reacted at room temperature for 1 h. After the reaction was completed as monitored by TLC, the reaction solution was washed three times with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (DCM: MeOH = 100: 1) to obtain compound P-7 (white solid, 154 mg, yield 30%). 11H NMR (600 MHz, CDCl3) δ: 8.68 (s, 1H), 8.55 (d, J = 8.1 Hz, 1H), 8.19 (s, 1H), 7.73 - 7.79 (m, 1H), 7.90 (s, 1H), 7.87 (d, J = 7.5 Hz, 1H), 7.32 - 7.57 (m, 9H), 7.16 (t, J = 7.5 Hz, 1H), 7.10 (d, J = 7.9 Hz, 1H), 6.69 (d, J = 46.8 Hz, 1H), 5.01 - 5.13 (m, 1H), 4.48 - 4.78 (m, 4H), 4.08 - 4.28 (m, 4H), 3.96 (s, 3H), 3.64 - 3.80 (m, 2H), 3.52 (s, 3H), 3.45 (s, 3H), 3.14 - 3.21 (m, 1H), 2.80 - 2.87 (m, 1H), 2.53 (s, 3H), 2.33 - 2.43 (m, 2H), 2.01 - 2.20 (m, 4H), 1.45 - 1.48 (m, 3H), 1.31 - 1.37 (m, 2H), 1.11 (s, 9H); 13 13C NMR (150 MHz, CDCl3) δ: 171.43, 170.09, 169.88, 168.22, 166.64, 163.74, 155.24, 151.11, 150.32, 149.19, 148.41, 147.45, 146.43, 132.50, 132.36, 131.64, 130.73, 129.48, 126.95, 126.41, 123.89, 122.13, 119.54, 117.47, 116.51, 109.36, 70.10, 58.79, 57.38, 56.86, 56.02, 48.85, 46.99, 41.36, 38.29, 35.99, 35.37, 32.60, 31.82, 31.58, 29.69, 26.54, 22.62, 22.27, 16.07; HRMS (ESI, positive) m / z calcd for C 53 H 64 N 11 O9S [M + H] + : 1030.4604; found 1030.4634.

[0114] Example 9

[0115] Synthesis of (2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-3-methoxybenzamido)piperidin-1-yl)-2-oxoethoxy)ethoxy)acetylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-8)

[0116]

[0117] Compound 15 was replaced with 3,6-octanedioic acid, and other synthesis methods were referred to Example 8. White solid 90.6 mg, yield 40%. 1 H NMR (600MHz, CDCl3) δ: 8.68 (s, 1H), 8.55 (d, J = 8.6Hz, 1H), 8.18 (s, 1H), 7.85-7.90 (m, 2H), 7.38-7.51 (m, 5H), 7.30-7.35 (m,3H),7.17(t,J=7.6Hz,1H),7.04-7.14(m,2H),6.78-6.84(m,1H),5.06(t,J=7.3Hz,1H),4.57-4.63(m,2H),4.45(t,J =23.2Hz,2H),4.17-4.23(m,2H),3.73-3.86(m,4H),3.67(s,3H),3.52(s,3H),3.44(s,3H),3.11-3.23(m,1H),2.76-2.8 7(m,1H),2.52(s,3H),2.30-2.37(m,1H),1.75-2.01(m,8H),1.48(d,J=7.1Hz,1H),9.01(s,9H); HRMS(ESI,positive)m / z calcd for C 55 H 68 N 11 O 10 S[M+H] + :1074.4866; found 1074.4873.

[0118] Example 10

[0119] Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-14-(4-(4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diaza-2-(amino)-3-methoxybenzamido)piperidin-1-yl)-4,14-dioxo-6,9,12-trioxa-3-azidothioalkyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-9)

[0120]

[0121] Compound 15 was replaced with 2,2'-((oxybis(ethane-2,1-diyl))bis(oxy))diacetic acid, and other synthesis methods were referred to Example 8. White solid 84 mg, yield 34%. 1 H NMR(600MHz, CDCl3)δ:8.65(s,H),8.48(dd,J=27.7,8.2Hz,1H),8.14(s,1H),7.85(s,1H),7.83(d,J=7.6Hz,1H ),7.32-7.49(m,9H),7.12(t,J=7.3Hz,1H),7.06(d,J=8.2Hz,1H),5.01-5.11(m,1H),4.46-4.68(m,4H),4.15- 4.23(m,2H),3.91-3.96(m,4H),3.62-3.71(m,8H),3.48(s,3H),3.40(s,3H),3.04-3.19(m,2H),2.67-2.83(m, 4H),2.51(s,3H),2.33-2.41(m,1H),2.05-2.13(m,2H),1.43-1.46(m,4H),1.38(d,J=6.5Hz,3H),1.04(s,9H); 13C NMR(150MHz, CDCl3)δ:172.47,171.88,171.39,169.57,169.29,167.88,165.09,155.64,152.47,151.68,15 0.56,149.77,148.72,144.70,133.85,133.72,133.01,132.12,130.87,127.60,127.80,125.23,123.42,121 .05,118.80,117.83,110.75,72.78,72.50,71.94,71.34,60.22,58.32,57.36,54.94,50.19,48.19,45.86,4 3.28,42.89,39.63,37.33,37.24,34.17,32.99,27.85,23.58,19.94,18.80,17.42; HRMS(ESI,positive)m / z calcd for C 57 H 72 N 11 O 11 S[M+H] + :1118.5128; found1118.5101.

[0122] Embodiment 11

[0123] Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-17-(4-(4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-(yl)amino)-3-methoxybenzamido)piperidin-1-yl)-4,17-dioxo-6,9,12,15-tetraoxo-3-azaheptadecanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (P-10)

[0124]

[0125] Compound 15 was replaced with 3,6,9,12-tetraoxatetradecane-1,14-dicarboxylic acid, and other synthesis methods were referred to Example 8. White solid 57 mg, yield 32%. 1H NMR(600MHz,DMSO-d6)δ:8.63(s,1H),8.48(d,J=8.3Hz,1H),8.13(s,1H),7.82(s,1H),7.80(d,J=7.9Hz,1H),7.54(d,J=7.3Hz,1H),7.45(s,1H),7.28-7.43(m,8H),7.10(t,J=7.6Hz,1H),7.04(d,J=8.3Hz,1H),6.76(s,1H),4.99-5.07(m,1H),4.69(t,J=7.9Hz,1H),4.57(d,J=9.0Hz,1H),4.51(d,J=12.8Hz,1H),4.45(s,1H),4.10-4.28(m,4H),3.95-4.00(m,2H),3.92(s,3H),3.83-3.92(m,2H),3.60-3.67(m,12H),9.45(s,3H),3.38(s,3H),3.06-3.16(m,1H),2.74(t,J=12.09Hz,1H),2.62(s,2H),2.48(s,3H),2.31-2.38(m,1H),2.03-2.11(m,2H),1.45-1.55(m,2H),1.43(d,J=6.9Hz,3H),1.01(s,9H); 13 C NMR(150MHz,DMSO-d6)δ:171.43,170.30,169.88,168.20,167.80,166.56,163.70,155.30,151.17,150.28,149.21,148.46,147.41,132.48,132.37,130.80,129.52,127.12,126.43,123.87,122.11,119.38,117.41,116.42,109.34,71.05,70.56,70.45,70.39,70.02,58.52,57.04,56.83,56.04,48.83,47.05,44.23,41.29,38.26,35.97,35.79,35.41,32.74,31.87,31.57,29.68,26.50,22.22,16.08,14.10;HRMS(ESI,positive)m / z calcd for C 59 H 76 N 11 O 12 S[M+H] +:1162.5390; found 1162.5424.

[0126] Example 12

[0127] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)piperidin-4-yl)-3-methoxybenzamide (P-11)

[0128]

[0129] Reagents and conditions: a) EDCI, HOBT, DIPEA, DCM, rt, 2h, yield 63%.

[0130] Step: Synthesis of compound P-11

[0131] Compound 8g (0.5 g, 1.03 mmol) and pomalidomide (331 mg, 1.23 mmol) were dissolved in dry DCM (20 mL), and EDCI (229 mg, 1.23 mmol), HOBT (167 mg, 1.23 mmol) and DIPEA (258 mg, 2.05 mmol) were added in sequence, and the mixture was reacted for 2 h at room temperature. After the reaction was completed, the reaction solution was washed with a saturated sodium chloride solution (20 mL × 3), dried over anhydrous sodium sulfate, and then separated and purified by silica gel column chromatography (DCM / MeOH = 100: 1) to obtain compound P-11 (yellow solid, 100 mg, yield 36%). 1H NMR(600MHz,DMSO-d6)δ:11.09(s,1H),8.45(s,1H),8.34(d,J=8.7Hz,1H),8.25(d,J=7.9Hz,1H),8.15(s,1H),7.66-7 .73(m,2H),7.58(dd,J=1.8,8.3Hz,1H),7.48-7.55(m,2H),7.35(d,J=7.1Hz,1H),7.26(d,J=7.9Hz,3H),7.16-7.20(m ,1H),5.10(dd,J=12.7,5.5Hz,1H),4.00-4.10(m,1H),3.94(s,3H),3.75(d,J=11.9Hz,3H),3.41(s,3H),3.36(s,3H), 3.03(t,J=12.8Hz,1H),2.84-2.93(m,1H),2.52-2.64(m,2H),2.00-2.09(m,1H),1.90-1.97(m,2H),1.78-1.89(m,2H); 13 C NMR(150MHz,DMSO-d6)δ:173.27,170.50,167.56,167.49,166.81,165.51,163.45,155. 62,152.80,150.31,149.57,148.14,136.22,134.16,133.04,132.20,131.73,128.50,12 6.59,124.50,124.06,121.83,120.65,118.31,118.04,116.96,115.02,109.98,56.53, 50.71,49.27,46.73,37.94,36.08,32.06,31.43,26.81,22.57; HRMS(ESI,positive)m / z calcd forC 39 H 38 N9O7[M+H] + :744.2889; found 744.2904.

[0132] Embodiment 13

[0133] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)glycyl)piperidin-4-yl)-3-methoxybenzamide (P-12)

[0134]

[0135] Reagents and conditions: a) EDCI, HOBT, DIPEA, DCM, rt, 1h, yield 80-90%; b) DCM, TFA, rt, 2h, yield 90-95%; c) EDCI, HOBT, DIPEA, DCM, rt, 2h, yield 60-65%.

[0136] Step a: Synthesis of compound 19

[0137] Compound 8g (500 mg, 1.03 mmol) and Boc-glycine (210 mg, 1.23 mmol) were dissolved in dry DCM (20 mL), and EDCI (287 mg, 1.54 mmol), HOBT (209 mg, 1.54 mmol) and DIPEA (387 mg, 1.54 mmol) were added in sequence under stirring, and the mixture was reacted at room temperature for 1 h. After the reaction was completed by TLC detection, the reaction solution was washed with saturated sodium chloride (20 mL×3), the organic layer was dried over anhydrous sodium sulfate, evaporated under reduced pressure, and separated and purified by silica gel column chromatography (hexane:EtOAc=4:1-1:1) to obtain compound 19 (yellow solid, 527 mg, yield 80%). 1 H NMR(600MHz, DMSO-d6)δ:8.46(s,1H),8.34(s,J=8.4Hz,1H),8.24(d,J=7.7Hz,1H),8.16(s,1H),7.70(dd,J=7.7,1.6H z,1H),7.56(dd,J=8.4,1.7Hz,1H),7.49-7.53(m,2H),7.26(d,J=8.1Hz,1H),7.16-7.20(m,1H),6.80-8.87(m,1H),4. 39(d,J=13.1Hz,1H),3.99-4.09(m,1H),3.94(s,3H),3.88(d,J=13.4Hz,1H),3.41(s,3H),3.35(s,3H),3.12(t,J=12. 9Hz, 1H), 2.95 (q, J = 6.5Hz, 1H), 2.64-2.71 (m, 1H), 2.32 (t, J = 6.9Hz, 2H), 1.84 (dd, J = 35.1, 10.5Hz, 2H), 1.38 (s, 9H).

[0138] Step b: Synthesis of compound P-12

[0139] Compound 19 (500 mg, 0.78 mmol) was placed in a 25 mL reaction bottle, 10 mL DCM was added to fully dissolve, TFA (273.6 mg, 2.33 mmol) was slowly added dropwise, and the reaction was allowed to react at room temperature for 2 h. After the reaction was completed by TLC monitoring, the reaction solution was distilled under reduced pressure without further purification to obtain a crude product of compound 20. Compound 20 and pomalidomide (248.4 mg, 0.93 mmol) obtained in the previous step were then dissolved in dry DCM (20 mL), and EDCI (229.2 mg, 1.16 mmol), HOBT (166.8 mg, 1.16 mmol) and DIPEA (309.6 mg, 2.33 mmol) were added in sequence, and the reaction was allowed to react at room temperature for 2 h. After the reaction was completed, the reaction solution was washed with saturated sodium chloride solution (20 mL×3), dried over anhydrous sodium sulfate, and distilled under reduced pressure. The mixture was separated and purified by silica gel column chromatography (DCM / MeOH=100:1) to obtain compound P-12 (yellow solid, 600 mg, yield 37%). 1 H NMR(600MHz,DMSO-d6)δ:11.11(s,1H),8.45(s,1H),8.34(d,J=8.3Hz,1H),8.22(d,J=7.9Hz,1H),8.16(s,1H),7.69(dd,J=7.7,1.5Hz,1H),7 .62(t,J=8.1Hz,1H),7.55(d,J=7.5Hz,1H),7.48-7.53(m,2H),7.25(d,J=8.5Hz,1H),7.18(t,J=7.2Hz,1H),7.06-7.15(m,2H),5.08(dd,J=12 .9,5.3Hz,1H),4.34-4.48(m,1H),4.15-4.33(m,2H),4.06-4.14(m,1H ),3.94-4.00(m,1H),3.93(s,3H),3.41(s,3H),3.36(s,3H),3.12-3.27 (m,1H),2.69-2.96(m,2H),2.50-2.65(m,2H),1.98-2.01(m,1H),1.86 -1.96(m,2H),2.69-2.96(m,2H),1.41-1.63(m,1H),1.13-1.35(m,1H); 13C NMR(150MHz,DMSO-d6)δ:173.26,170.53,169.28,167.82,167.48,166.60,165.61,16 3.44,155.60,152.81,149.56,148.15,145.90,136.64,133.04,132.50,132.20,131. 77,128.44,126.58,124.06,121.83,120.59,118.76,118.31,118.01,111.28,110.02,56.53,49.07,46.96,44.14,43.31,41.30,37.94,36.07,32.32,31.64,31.46,22.62.

[0140] Embodiment 14

[0141] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)amino)propanoyl)piperidin-4-yl)-3-methoxybenzamide (P-13)

[0142] Step a: Synthesis of compound 19-1

[0143]

[0144] Compound 18 was replaced with Boc-β-alanine, and other synthesis methods were referred to Example 13. 286 mg of white solid, yield 88%. 1H NMR(600MHz, DMSO-d6)δ:8.45(s,1H),8.33(d,J=7.9Hz,1H),8.23(d,J=7.6Hz,1H),8.14(s,1H),7.69(dd,J=7.8,1.6Hz, 1H),7.55(dd,J=8.3,1.6Hz,1H),7.49-7.54(m,2H),7.25(d,J=8.1Hz,1H),7.17(t,J=7.0Hz,1H),6.79-6.87(m,1H),4.3 8(d,J=13.2Hz,1H),4.00-4.09(m,1H),3.93(s,3H),3.87(d,J=13.3Hz,1H),3.40(s,3H),3.34(s,3H),3.11(t,J=13.0Hz ,1H),2.94(q,J=6.5Hz,2H),2.64-2.70(m,1H),2.31(t,J=7.0Hz,1H),1.75-1.90(m,2H),1.58-1.62(m,2H),1.37(s,9H).

[0145] Step b: Synthesis of compound P-13

[0146]

[0147] The synthesis method is as in Example 13. Yellow solid 80 mg, yield 29%. 1 H NMR(600MHz,DMSO-d6)δ:8.54(dd,J=8.7,3.1Hz,1H),8.42(s,1H),8.34(s,1H),8.20(s,1H),7.81-7.94(m,2H),7.49-7.58(m,1H),7 .40-7.49(m,2H),2.49(dd,J=8.6,1.9Hz,1H),7.29(s,1H),7.15-7.19(m,1H),7.08-7.15(m,2H),7.00(dd,J=8.7,3.1Hz,1H),6.48-6 .65(m,1H),6.39(dd,J=36.7,8.3Hz,1H),4.87-4.96(m,1H),4.63-4.72(m,1H),4.15-4.26(m,1H),3.99(d,J=1.8Hz,3H),3.72-3.88( m,2H),3.63-3.72(m,1H),3.52(s,3H),3.49(s,3H),3.18(t,J=12.4Hz,1H),2.69-2.91(m,4H),2.54-2.64(m,1H),2.00-2.14(m,3H);13 C NMR(150MHz,DMSO-d6)δ:170.97,169.35,169.05,168.71,167.61,166.70,163.70,15 5.31,151.23,149.23,147.46,146.55,136.28,132.59,132.48,127.17,126.47,123. 86,122.14,119.24,117.42,116.70,116.59,116.37,111.77,110.37,109.38,56.03,48.99,47.12,44.79,41.10,38.72,35.95,32.67,32.24,31.79,31.44,29.69,22.66.

[0148] Embodiment 15

[0149] Synthesis of 4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidin[5,4-b][1,4]diazepin-2-yl)-amino)-N-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)piperidin-4-yl)-3-methoxybenzamide (P-14)

[0150] Step a: Synthesis of compound 19-2

[0151]

[0152] Compound 18 was replaced with Boc-5-aminopentanoic acid, and other synthesis methods were referred to Example 13. 396 mg of white solid, yield 90%. 1H NMR (600MHz, DMSO-d6) δ: 8.45 (s, 1H), 8.33 (d, J=7.6Hz, 1H), 8.10-8.21 (m, 1H), 7.69 (dd, J=7.7, 1.6Hz, 1H), 7.54 (dd, J= 8.4,1.6Hz,1H),7.47-7.53(m,2H),7.25(d,J=8.4Hz,1H),7.18(t,J=7.3Hz,1H),6.79(t,J=5.4Hz,1H),4.38(d,J=13.2H z,1H),3.99-4.10(m,1H),3.93(s,3H),3.86-3.92(m,1H),3.41(s,3H),3.35(s,3H),3.11(t,J=12.3Hz,1H),2.92(q,J=6 .7Hz,1H),2.67(t,J=11.7Hz,1H),2.31(t,J=7.3Hz,2H),1.84(dd,J=37.0,11.0Hz,2H),1.44-1.52(m,3H),1.37(s,9H).

[0153] Step b: Synthesis of compound P-14

[0154]

[0155] The synthesis method is as in Example 13, step b. Yellow solid 200 mg, yield 41%. 1H NMR(600MHz,DMSO-d6)δ:11.09(s,1H),8.45(s,1H),8.33(d,J=8.7Hz,1H),8.17 (s,1H),8.15(s,1H),7.69(dd,J=7.8,1.7Hz,1H),7.59(t,J=8.1Hz,1H),7.48-7 .56(m,3H),7.25(d,J=8.4Hz,1H),7.18(t,J=7.5Hz,1H),7.12(d,J=8.6Hz,1H), 7.02(d,J=7.0Hz,1H),6.57(t,J=5.6Hz,1H),5.05(dd,J=12.8,5.5Hz,1H),4.38 (d,J=12.9Hz,1H),3.99-4.99(m,1H),3.93(s,3H),3.86-3.92(m,1H),3.41(s,3 H),3.35(s,3H),3.08-3.18(m,2H),2.83-2.95(m,1H),2.64-2.71(m,1H),2.54- 2.61(m,1H),2.51-2.54(m,1H),2.39(t,J=7.3,1H),2.00-2.05(m,1H),1.78-1. 89(m,2H),1.56-1.68(m,4H),1.33-1.53(m,3H); HRMS(ESI,positive)m / zcalcd for C 44 H 47 N 10 O8[M+H] + :843.3573; found 843.3575.

[0156] Example 16

[0157] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)amino)hexanoyl)piperidin-4-yl)-3-methoxybenzamide (P-15)

[0158] Step a: Synthesis of compound 19-3

[0159]

[0160] Compound 18 was replaced with 6-((tert-butoxycarbonyl)amino)hexanoic acid, and other synthetic methods were referred to Example 13. 256 mg of white solid, yield 86%. 1H NMR(600MHz, DMSO-d6)δ:8.45(s,1H),8.33(d,J=8.3Hz,1H),8.19(d,J=7.5Hz,1H),8.15(s,1H),7.69(dd,J=7.8,1.7Hz,1H),7.5 5(d,J=8.4Hz,1H),7.45-7.53(m,2H),7.25(d,J=8.3Hz,1H),7.18(t,J=7.3Hz,1H),6.77(t,J=5.6Hz,1H),4.38(d,J=13.2Hz,1H) ,4.00-4.08(m,1H),3.93(s,3H),3.89(d,J=13.7Hz,1H),3.41(s,3H),3.35(s,3H),3.11(t,J=12.1Hz,1H),2.90(t,J=6.8Hz,2H) ,2.66(t,J=11.9Hz,1H),2.30(t,J=7.3Hz,2H),1.83(dd,J=36.4,10.4Hz,2H),1.44-1.53(m,4H),1.37(s,9H),1.23-1.29(m,4H).

[0161] Step b: Synthesis of compound P-15

[0162]

[0163] The synthesis method is as in Example 13, step b. Yellow solid 90 mg, yield 28%. 11H NMR (600 MHz, DMSO-d6) δ: 11.09 (s, 1H), 8.45 (s, 1H), 8.33 (d, J = 8.5 Hz, 1H), 8.13 - 8.20 (m, 2H), 6.89 (dd, J = 7.8, 1.8 Hz, 1H), 7.56 - 7.61 (m, 1H), 7.53 - 7.56 (m, 1H), 7.47 - 7.53 (m, 2H), 7.25 (d, J = 8.3 Hz, 1H), 7.18 (t, J = 7.2 Hz, 1H), 7.10 (d, J = 8.7 Hz, 1H), 7.02 (d, J = 6.9 Hz, 1H), 6.54 (t, J = 5.8 Hz, 1H), 6.05 (dd, J = 5.6, 13.0 Hz, 1H), 4.38 (d, J = 13.2 Hz, 1H), 3.99 - 4.08 (m, 1H), 3.93 (s, 3H), 3.87 - 3.92 (m, 1H), 3.41 (s, 3H), 3.35 (s, 3H), 3.27 - 3.32 (m, 2H), 3.11 (t, J = 12.1 Hz, 1H), 2.83 - 2.92 (m, 1H), 2.56 - 2.62 (m, 1H), 2.51 - 2.56 (m, 1H), 2.29 - 2.37 (m, 2H), 2.00 - 2.06 (m, 1H), 1.77 - 1.90 (m, 2H), 1.50 - 1.64 (m, 4H), 1.24 - 1.41 (m, 4H); 13 13C NMR (150 MHz, DMSO-d6) δ: 173.25, 170.83, 170.55, 169.42, 167.76, 167.48, 165.50, 163.43, 155.60, 152.80, 149.56, 148.14, 146.91, 136.75, 133.04, 132.67, 132.20, 131.75, 128.45, 126.59, 124.05, 121.83, 120.57, 118.31, 118.00, 117.66, 110.85, 109.97, 109.45, 56.52, 49.02, 47.09, 44.58, 42.26, 40.75, 37.94, 36.07, 32.72, 31.80, 31.44, 29.04, 26.61, 25.16, 22.63; HRMS (ESI, positive) m / z calcd for C 44 H 47 N 10 O8 [M + H] + : 857.3429; found 3757.

[0164] Example 17

[0165] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)amino)heptanoyl)piperidin-4-yl)-3-methoxybenzamide (P-16)

[0166] Step a: Synthesis of compound 19-4

[0167]

[0168] Compound 18 was replaced with 7-(N-tert-butyloxycarbonylamino)heptanoic acid, and other synthesis methods were referred to Example 13. 240 mg of white solid, yield 82%. 1 H NMR (600MHz, CDCl3) δ: 8.44 (s, 1H), 8.32 (d, J = 8.3Hz, 1H), 8.23 ​​(d, J = 7.7Hz, 1H), 7.69 (dd, J = 7.7, 1.2Hz, 1H), 7.55 (d, J=8.5Hz,1H),7.48-7.54(m,2H),7.25(d,J=8.4Hz,1H),7.17(t,J=7.5Hz,1H),4.39(d,J=12.8Hz,1H),4.01-4.10(m,1H ),3.93(s,3H),3.89(d,J=12.8Hz,1H),3.54-3.69(m,4H),3.40(s,3H),3.35(s,3H),3.10(t,J=12.5Hz,1H),2.66(t,J =12.0Hz,1H),2.55-2.63(m,2H),2.31(t,J=7.5Hz,2H),1.83(dd,J=36.4,11.5Hz,2H),1.34-1.54(m,6H),1.28(s,9H).

[0169] Step b: Synthesis of compound P-16

[0170]

[0171] The synthesis method is as shown in step b of Example 13. Yellow solid 90 mg, yield 36%. 1H NMR(600MHz,DMSO-d6)δ:11.09(s,1H),8.44(s,1H),8.33(d,J=8.5Hz,1H),8.16(d,J=8.1Hz,1H),8.14(s,1H),7.69(dd,J=7.8,1.6Hz,1H),7.55-7.59(m,1H),7.54(dd,J=8.6,1.8Hz,1H),7.47-7.52(m,2H),7.25(d,J=8.3Hz,1H),7.17(t,J=7.8Hz,1H),7.01(d,J=6.9Hz,1H),6.53(t,J=5.7Hz,1H),5.05(dd,J=12.9,5.4Hz,1H),4.39(d,J=12.5Hz,1H),4.00-4.99(m,1H),3.94(s,3H),3.88(d,J=12.8Hz,1H),3.41(s,3H),3.35(s,3H),3.29(q,J=6.5Hz,1H),3.11(t,J=12.4Hz,1H),2.82-2.93(m,1H),2.66(t,J=11.6Hz,1H),2.50-2.62(m,2H),2.31(t,J=7.5Hz,1H),2.00-2.06(m,1H),1.79-1.88(m,2H),1.55-1.60(m,2H),1.49-1.53(m,2H),1.33-1.38(m,4H),1.21-1.26(m,2H); 13 C NMR(150MHz,DMSO-d6)δ:173.25,170.87,170.54,169.43,167.76,167.48,165.51,163.43,155.59,152.77,149.55,148.11,146.91,136.73,133.03,132.67,132.20,131.75,128.42,126.58,124.04,121.83,120.58,118.29,117.95,117.63,110.84,109.96,109.51,56.51,55.36,49.02,47.10,44.59,42.28,40.74,37.93,36.07,32.73,31.81,31.44,31.41,29.06,29.00,26.72,25.38,22.93,22.62,22.51,14.41;HRMS(ESI,positive)m / z calcd for C 45 H 49 N10 O8[M+H] + :871.3886; found 871.3871.

[0172] Embodiment 18

[0173] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)amino)octanoyl)piperidin-4-yl)-3-methoxybenzamide (P-17)

[0174] Step a: Synthesis of compound 19-5

[0175]

[0176] Compound 18 was replaced with Boc-8-aminooctanoic acid, and other synthesis methods were referred to Example 13. 251 mg of white solid, yield 85%. 1 H NMR (600MHz, CDCl3) δ: 8.50 (d, J = 7.8Hz, 1H), 8.29 (d, J = 7.1Hz, 1H), 8.16 (s, 1H), 7.86-7.95 (m, 1H), 7.84 (dd, J = 7.9, 1.4Hz, 1H), 7.47 (t, J = 7.5 Hz,1H),7.38-7.45(m,2H),7.29(d,J=8.5Hz,1H),7.13(t,J=7.6Hz,1H),7.07(s,1H),7.06(s,1H),6.86(d,J=8.6Hz,1H),6.21(t,J=5.7Hz,1H) ,6.07(d,J=7.5Hz,1H),4.89(dd,J=12.3,5.2Hz,1H),4.60(d,J=12.7Hz,1H),4.15-4.25(m,1H),3.97(s,3H),3.86(d,J=12.7Hz,1H),3.49(s,3 H),3.42(s,3H),3.25(q,J=6.6Hz,2H),3.19(t,J=12.5Hz,1H),2.64-2. 90(m,4H),2.33(dd,J=12.7,7.5Hz,2H),1.96-2.18(m,3H),1.36(s,9H).

[0177] Step b: Synthesis of compound P-17

[0178]

[0179] The synthesis method is as in Example 13, step b. Yellow solid 60 mg, yield 28%. 1 H NMR(600MHz, CDCl3)δ:8.50(d,J=7.8Hz,1H),8.29(d,J=7.1Hz,1H),8.16(s,1H),7.86-7.95(m,1H),7.84(dd,J=7.7,1.4Hz,1H),7.47(t,J=7.5H z,1H),7.39-7.45(m,2H),7.29(d,J=8.6Hz,1H),7.13(t,J=7.7Hz,1H),7 .07(d,J=7.3Hz,1H),6.86(d,J=8.6Hz,1H),6.21(t,J=5.6Hz,1H),6.07( d,J=7.7Hz,1H),4.89(dd,J=12.3,5.3Hz,1H),4.61(d,J=12.8Hz,1H),4. 15-4.25(m,1H),3.97(s,3H),3.82-3.91(m,1H),3.49(s,3H),3.42(s,3H ),3.25(q,J=6.8Hz,2H),3.19(t,J=12.3Hz,1H),2.64-2.92(m,4H),2.26 -2.41(m,2H),1.97-2.18(m,3H),1.52-1.70(m,10H),1.34-1.39(m,4H); 13 C NMR(150MHz, CDCl3)δ:172.93,172.35,170.92,169.74,169.55,169.00,167.90,165.14,14 8.95,148.40,137.50,133.86,133.77,127.84,125.29,120.36,118.80,118.03,117.89,11 2.78,111.26,110.69,57.41,50.27,48.63,45.96,43.98,42.12,39.66,39.66,37.37,34.7 0,34.41,33.33,32.79,30.66,30.50,30.42,28.12,26.60,24.20; HRMS(ESI,positive)m / z calcd for C 47 H 53 N 10 O2[M+H] + :885.4042; found 885.4048.

[0180] Embodiment 19

[0181] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2-(2-(2-((2-(2-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)acetyl)piperidin-4-yl)-3-methoxybenzamide (P-18)

[0182]

[0183] Reagents and conditions: a) EDCI, HOBT, DIPEA, DCM, rt, 1h, yield 68%; b) DCM, H2, Pd / C, rt, overnight, yield 85%; c) EDCI, HOBT, DIPEA, DCM, rt, 1h, yield 78%.

[0184] Step a: Synthesis of compound 22

[0185] Compound 8g (1.0 g, 2.05 mmol) and compound 21 (662 mg, 2.46 mmol) were dissolved in dry DCM (50 mL), and EDCI (458 mg, 2.46 mmol), HOBT (333 mg, 2.46 mmol), and DIPEA (516 mg, 4.10 mmol) were added in sequence, and the mixture was reacted for 2 h at room temperature. After the reaction was completed by TLC monitoring, the reaction solution was distilled under reduced pressure, and then separated and purified by silica gel column chromatography (DCM / MeOH=100:0.5) to obtain compound 22 (white solid, 963 mg, yield 68%). 1H NMR(600MHz, CDCl3)δ:8.53(d,J=8.2Hz,1H),8.17(s,1H),7.94(s,1H),7.85(dd,J=7.8,1.7Hz,1H),7.4 3-7.49(m,2H),7.41(d,J=1.8Hz,1H),7.17-7.14(m,1H),7.12(d,J=8.3Hz,1H),6.61(s,1H),6.38(d,J=8 .2Hz,1H),4.52(d,J=13.0Hz,1H),4.21-4.67(m,3H),3.99(s,3H),3.78-3.84(m,1H),3.70-3.77(m,10H ),3.51(s,3H),3.46(s,3H),3.15-3.20(m,2H),2.75-2.81(m,1H),1.97-2.10(m,2H),1.61-1.74(m,2H).

[0186] Step b: Synthesis of compound P-18

[0187] Compound 22 (0.5 g, 0.71 mmol) was dissolved in DCM (20 mL), and 0.1 g of palladium carbon was added, and the reaction was continued overnight at room temperature under hydrogen conditions. After the reaction was completed by TLC monitoring, the reaction solution was filtered through diatomaceous earth, and the filtrate was distilled under reduced pressure without further purification to obtain 400 mg of the crude product of compound 23. Compound 23 (300 mg, 0.44 mmol) and pomalidomide (138 mg, 0.53 mmol) were then dissolved in dry DCM (15 mL), and EDCI (115 mg, 0.66 mmol), HOBT (83 mg, 0.66 mmol), and DIPEA (194 mg, 1.50 mmol) were added in sequence, and the reaction was continued for 2 h at room temperature. After the reaction was completed, the reaction solution was washed with a saturated sodium chloride solution (20 mL×3), and the organic layer was dried over anhydrous sodium sulfate, evaporated under reduced pressure, and then separated and purified by silica gel column chromatography (DCM / MeOH=100:1) to obtain compound P-18 (yellow solid, 508.9 mg, yield 78%). 1H NMR(600MHz,DMSO-d6)δ:11.09(s,1H),8.45(s,1H),8.32(d,J=8.5Hz,1H),8.17(d,J=7.7Hz,1H),8.14(s,1H),7.69(dd,J=7.8,1.7Hz,1H),7.47-7.58(m,4H),7.25(d,J=8.4Hz,1H),7.18(t,J=7.8Hz,1H),7.12(d,J=8.6Hz,1H),7.02(d,J=7.1Hz,1H),6.59(t,J=5.8Hz,1H),5.05(dd,J=12.9,5.6Hz,1H),4.32(d,J=14.0Hz,1H),4.09-4.13(m,1H),4.00-4.07(m,1H),3.92(s,3H),3.83(d,J=14.2Hz,1H),3.61(t,J=5.6Hz,1H),3.51-3.59(m,7H),3.42-3.51(m,3H),3.41(s,3H),3.35(s,3H),3.16(d,J=5.0Hz,1H),3.02-3.10(m,1H),2.82-2.91(m,1H),2.71(t,J=12.5Hz,1H),2.55-2.64(m,1H),1.94-2.06(m,2H),1.84(t,J=13.4Hz,1H),1.32-1.56(m,3H); 13 C NMR(150MHz,DMSO-d6)δ:173.25,170.52,169.40,167.74,167.48,165.52,163.44,155.59,152.80,149.56,148.12,148.86,136.67,133.04,132.55,132.20,131.74,128.42,126.59,124.05,121.83,120.59,118.31,117.98,117.86,111.12,109.97,109.72,70.25,70.14,70.07,69.36,49.03,46.98,43.93,42.15,40.87,37.94,36.07,32.57,31.71,31.44,22.61;HRMS(ESI,positive)m / z calcd for C 47 H 53 N 10 O 11 [M+H] +:933.3890; found933.3867.

[0188] Embodiment 20

[0189] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(2-((2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoindole-4-yloxy)acetyl)piperidin-4-yl)-3-methoxybenzamide (P-19)

[0190]

[0191] Reagents and conditions: a) DIPEA, DMF, 80°C, 8h, yield 58%; b) DCM, TFA, rt, 2h, yield 90-95%; c) EDCI, HOBT, DIPEA, DCM, rt, 1h, yield 38%.

[0192] Step: Synthesis of compound P-19

[0193] Compound 24 (110 mg, 0.40 mmol) and compound 25 (94 mg, 0.48 mmol) were dissolved in dry DMF (10 mL), DIPEA (104 mg, 0.80 mmol) was added, and the mixture was transferred to 80°C and stirred overnight. After the reaction was completed by TLC, the reaction solution was poured into 300 mL of water, extracted with ethyl acetate (20 mL×3), the organic layer was collected, washed 3 times with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated and purified by silica gel column chromatography (DCM / MeOH=100:1) to obtain compound 26 (yellow solid, 90 mg, yield 58%).

[0194] Compound 26 (90 mg, 0.23 mmol) was placed in a 25 mL reaction bottle, 10 mL DCM was added to fully dissolve, TFA (2 mL) was slowly added dropwise, and the reaction was allowed to react at room temperature for 2 h. After the reaction was completed by TLC monitoring, the reaction solution was distilled under reduced pressure without further purification to obtain the crude product of compound 27. Compound 8g (113 mg, 0.23 mmol) and compound 27 (92 mg, 0.28 mmol) were dissolved in dry DCM (10 mL), and EDCI (53 mg, 0.28 mmol), HOBT (38 mg, 0.28 mmol), and DIPEA (60 mg, 0.46 mmol) were added in sequence, and the reaction was allowed to react at room temperature for 2 h. After the reaction was completed by TLC monitoring, the reaction solution was distilled under reduced pressure, and then separated and purified by silica gel column chromatography (DCM / MeOH=100:1) to obtain compound P-19 (yellow solid, 70 mg, yield 38%). 1 H NMR (600MHz, DMSO-d6) δ: 11.12 (s, 1H), 8.45 (s, 1H), 8.34 (d, J = 8.6Hz, 1H), 8.2 3(d,J=7.6Hz,1H),8.16(s,1H),7.78(t,J=8.1Hz,1H),7.69(dd,J=7.8,1.4Hz, 1H),7.56(d,J=8.4Hz,1H),7.48-7.53(m,2H),7.46(d,J=7.4Hz,1H),7.33(d,J =8.7Hz,1H),7.26(d,J=8.4Hz,1H),7.18(t,J=7.3Hz,1H),5.21-5.34(m,1H),5 .11(dd,J=12.9,5.5Hz,1H),4.3(d,J=11.3Hz,1H),4.04-4.14(m,1H),3.94(s, 3H),3.86(d,J=13.1Hz,1H),3.41(s,3H),3.36(s,3H),3.20(t,J=11.9Hz,1H), 2.85-2.94(m,1H),2.80(t,J=11.6Hz,1H),2.53-2.64(m,1H),2.01-2.08(m,1H ),1.82-1.95(m,2H),1.58-1.66(m,1H),1.41-1.52(m,1H),1.16-1.31(m,2H); 13C NMR(150MHz,DMSO-d6)δ:170.24,170.39,167.49,167.27,165.71,165.62,165.28,163.44,155.1 6,155.60,152.80,149.56,148.14,136.97,133.60,133.04,132.20,1321.78,128.44,126.58,12 4.06,121.84,120.62,118.30,117.99,116.65,115.92,110.02,66.65,60.21,56.53,49.24,46.9 6,43.59,41.10,37.94,36.08,32.40,31.61,31.42,22.47,21.22,14.55; HRMS(ESI,positive)m / z calcd for C 41 H 40 N9O9[M+H] + :802.2944; found 802.2959.

[0195] Embodiment 21

[0196] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl)hexa-5-ynyl)piperidin-4-yl)-3-methoxybenzamide (P-20)

[0197]

[0198] Reagents and conditions: a) DIPEA, DMF, 90°C, 5h, yield 69%; b) EDCI, HOBT, DIPEA, DCM, 2h, yield 85%.

[0199] Step a: Synthesis of compound 30

[0200] The synthesis method refers to the literature (Wang, B., et al., Eur J Med Chem, 2021, 219: 113425.).

[0201] Step b: Synthesis of compound P-20

[0202] Compound 8g (83 mg, 0.17 mmol) and compound 30 (67 mg, 0.21 mmol) were dissolved in dry DCM (10 mL), and EDCI (40 mg, 0.21 mmol), HOBT (28 mg, 0.21 mmol), and DIPEA (27 mg, 0.34 mmol) were added in sequence, and the mixture was reacted for 2 h at room temperature. After the reaction was completed by TLC monitoring, the reaction solution was distilled under reduced pressure, and then separated and purified by silica gel column chromatography (DCM / MeOH=100:1) to obtain compound P-20 (yellow solid, 50 mg, yield 37%). 1 H NMR(600MHz,DMSO-d6)δ:10.99(d,J=4.5Hz,1H),8.45(s,1H),8.33(d,J=8.5 Hz,1H),8.11-8.19(m,2H),7.67-7.72(m,2H),7.63(d,J=7.6Hz,1H),7.47-7. 59(m,6H),7.26(d,J=8.5Hz,1H),7.18(t,J=7.8Hz,1H),5.16(dd,J=13.2,5. 3Hz,1H),4.47(d,J=17.94Hz,1H),4.37(d,J=13.8Hz,1H),4.32(d,J=17.5Hz, 1H),4.01-4.07(m,1H),3.93(s,3H),3.91(s,1H),3.41(s,3H),3.37(s,3H), 3.09-3.16(m,1H),2.88-2.97(m,1H),2.64-2.71(m,1H),2.56-2.62(m,1H),2 .40(t,J=7.0Hz,1H),1.97-2.04(m,1H),1.78-1.89(m,1H),1.67-1.73(m,2H) ,1.58-1.64(m,2H),1.44-1.50(m,1H),1.34-1.41(m,1H),1.21-1.29(m,1H); 13C NMR(150MHz,DMSO-d6)δ:173.31,171.43,170.70,168.12,167.46,165.49,163.43,155.59,152 .80,149.55,148.13,144.31,134.37,133.02,132.43,132.18,131.73,131.16,129.04,128.44 ,126.57,124.04,123.06,121.81,120.55,119.28,118.30,118.00,109.96,96.67,56.50,52.03,47.42,47.07,44.52,37.92,36.05,32.69,32.14,31.78,31.69,28.09,24.55,22.76,19.04.

[0203] Embodiment 22

[0204] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(7-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl)hept-6-ynyl)piperidin-4-yl)-3-methoxybenzamide (P-21)

[0205] Step a: Synthesis of compound 30-1

[0206]

[0207] Compound 29 was replaced with 6-heptynoic acid, and the other synthetic methods were referred to step a of Example 21. 325 mg of light blue solid, yield 55%. 1 H NMR(600MHz, DMSO-d6)δ:12.04(s,1H),10.98(s,1H),7.71(d,J=7.3Hz,1H),7.63(d,J=7.5Hz,1H),7.52(t,J=7.5Hz,1H),7.37-7.43(m,2H),5.14(d d,J=13.2,4.5Hz,1H),4.38(dd,J=85.2,17.5Hz,2H),2.87-2.96(m,1H),2 .57-2.64(m,1H),2.25-2.34(m,1H),1.94-2.06(m,1H),1.52-1.73(m,4H).

[0208] Step b: Synthesis of compound P-21

[0209]

[0210] The synthesis method is as shown in step b of Example 21. 90 mg of yellow solid, yield 35%. 1 H NMR(600MHz, DMSO-d6)δ:10.99(d,J=3.9Hz,1H),8.45(s,1H),8.33(d,J=8.1Hz,1H),8.03-8.23(m,2H),7.70(t,J=8.4Hz,2H),7.6 3(d,J=7.6Hz,1H),7.44-7.58(m,4H),7.25(d,J=8.4Hz,1H),7.18(t,J=7.3Hz,1H),5.16(dd,J=12.8,4.8Hz,1H),4.27-4.42(m,2H) ,4.01-4.06(m,1H),3.93(s,3H),3.90(s,1H),3.41(s,3H),3.36(s,3H),3.12(t,J=12.9Hz,1H),2.85-2.97(m,1H),2.67(t,J=11.8 Hz,1H),2.59(d,J=17.0Hz,1H),2.39(t,J=7.1Hz,1H),1.99-2.04(m,1H),1.76-1.90(m,2H),1.55-1.75(m,4H),1.32-1.19(m,3H); 13 C NMR(150MHz,DMSO-d6)δ:173.30,171.42,168.12,167.46,165.50,163.43,155.58,152.78,149.54,1 48.13,144.30,134.37,133.02,132.43,132.18,131.73,129.04,128.44,126.57,124.04,123.05,12 1.81,120.55,119.28,118.29,118.00,109.97,96.67,77.07,55.50,52.04,47.42,47.07,44.52,40. 73,37.92,36.05,32.70,32.15,31.78,31.68,28.12,124.55,22.77,19.05; HRMS(ESI,positive)m / z calcd for C 46 H 48 N9O7[M+H] + :838.3677; found 838.3657.

[0211] Embodiment 23

[0212] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(8-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl)oct-7-ynyl)piperidin-4-yl)-3-methoxybenzamide (P-22)

[0213] Step a: Synthesis of compound 30-2

[0214]

[0215] Compound 29 was replaced with 7-octynoic acid, and the other synthetic methods were referred to step a of Example 21. 371 mg of light blue solid, yield 51%. 1 H NMR(600MHz,DMSO-d6)δ12.00(s,1H),10.97(s,1H),7.75-7.67(m,1H),7.65 -7.57(m,1H),7.51(t,J=7.6Hz,1H),5.14(dd,J=13.3,5.0Hz,1H),4.45(d,J= 17.7Hz,1H),4.32(d,J=17.7Hz,1H),2.98-2.89(m,1H),2.62-2.56(m,1H),2. 54-2.48(m,3H),2.25(t,J=7.2Hz,2H),2.14-1.93(m,1H),1.77-1.26(m,6H); 13 C NMR(150MHz,DMSO-d6)δ174.87,173.34,171.46,168.16,144.24,134.54,132.45,129.07,123.07,119.3 4,96.74,76.92,52.15,47.48,34.06,31.69,28.31,28.24,24.51,22.84,19.16; HRMS(ESI,positive)m / z calcd for C 21 H 23 N2O5 + 383.1597,found[M+H] + 383.2847

[0216] Step b: Synthesis of compound P-22

[0217]

[0218] The synthesis method is as shown in step b of Example 21. 80 mg of yellow solid, yield 40%. 1 H NMR(600MHz,DMSO-d6)δ:11.01(s,1H),8.45(s,1H),8.33(d,J=8.4Hz,1H) ,8.01-8.21(m,2H),7.66-7.73(m,2H),7.64(d,J=7.7Hz,1H),7.47-7.58(m ,4H),7.25(d,J=8.4Hz,1H),7.17(t,J=3.7Hz,1H),5.15(dd,J=13.6,5.1H z,1H),4.39(dd,J=84.3,18.0Hz,2H),4.38(d,J=12.5Hz,1H),4.00-4.12(m ,1H),3.93(s,3H),3.90(d,J=14.3Hz,1H),3.40(s,3H),3.35(s,3H),3.11 (t,J=12.8Hz,1H),2.87-2.96(m,1H),2.57-2.70(m,2H),2.44-2.50(m,2H) ,2.35(t,J=7.3Hz,1H),1.97-2.05(m,1H),1.83(dd,J=34.5,10.6Hz,2H),1 .55-1.62(m,3H),1.43-1.50(m,3H),1.35-1.40(m,1H),1.22-1.27(m,1H); 13 C NMR(150MHz,DMSO-d6)δ:173.27,171.41,170.82,168.11,167.46,165.52,163.42,155.58,152.77,14 9.54,148.11,144.20,134.50,133.01,132.44,132.18,131.74,129.02,128.44,126.57,124.03,123.0 2,121.82,120.56,119.32,118.28,117.97,109.97,96.78,76.89,56.51,52.13,47.45,47.09,44.55, 40.73,37.91,36.05,32.71,31.78,31.67,28.59,28.37,24.91,22.80,19.17; HRMS(ESI,positive)m / z calcd for C 47 H 48 N9O7[MH] - :850.3682; found850.3685.

[0219] Embodiment 24

[0220] Synthesis of 4-(((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimidinyl[5,4-b][1,4]diazepin-2-yl)amino)-N-(1-(10-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl)dec-9-ynyl)piperidin-4-yl)-3-methoxybenzamide (P-23)

[0221] Step a: Synthesis of compound 30-3

[0222]

[0223] Compound 29 was replaced with dec-9-ynoic acid, and the other synthetic methods were referred to step a of Example 21. 331 mg of light blue solid, yield 59%. 1 H NMR (600MHz, DMSO-d6) δ: 11.96 (s, 1H), 10.99 (s, 1H), 7.70 (d, J = 7.6Hz, 1H), 7.63 (d, J = 7.3Hz, 1H),7.51(t,J=7.6Hz,1H),7.29-7.41(m,1H),5.14(dd,J=13.4,5.0Hz,1H),4.37(dd,J=82.3, 17.6Hz,1H),2.87-2.96(m,1H),2.56-2.63(m,1H),2.40-2.49(m,3H),2.19(t,J=7.5Hz,2H),1 .93-2.06(m,1H),1.53-1.60(m,2H),1.46-1.53(m,2H),1.38-1.56(m,2H),1.24-1.35(m,4H).

[0224] Step b: Synthesis of compound P-23

[0225]

[0226] 60 mg of yellow solid, yield 38%. 1H NMR(600MHz,DMSO-d6)δ:11.02(s,1H),8.46(s,1H),8.34(d,J=8.4Hz,1H),8.10-8.22(m,2H),7.71(t,J=7.7Hz,1H),7.64(d,J=8.4Hz,1H),7.47-7.60(m,4H),7.26(d,J=8.4Hz,1H),7.19(t,J=7.7Hz,1H),5.16(dd,J=5.1,12.5Hz,1H),4.39(dd,J=80.3,17.4Hz,2H),4.39(d,J=12.2Hz,1H),4.00-4.10(m,1H),3.94(s,3H),3.89(d,J=12.5Hz,1H),3.42(s,3H),3.36(s,3H),3.11(t,J=13.2Hz,1H),2.88-2.98(m,1H),2.67(t,J=12.5Hz,1H),2.61(d,J=17.3Hz,1H),2.41-2.49(m,2H),2.32(t,J=7.6Hz,2H),2.00-2.07(m,1H),1.85(dd,J=11.8,35.3Hz,1H),1.55-1.63(m,2H),1.49-1.55(m,2H),1.42-1.46(m,2H),1.22-1.36(m,6H),0.81-0.90(m,1H); 13 C NMR(150MHz,DMSO-d6)δ:173.28,171.42,170.89,168.10,167.45,165.49,163.41,155.57,152.76,149.53,148.09,144.16,134.47,133.01,132.41,132.18,131.73,129.03,128.41,126.56,124.02,123.02,121.81,120.56,119.30,118.27,117.94,109.94,96.83,76.83,56.49,52.10,47.41,47.09,44.56,40.71,37.91,36.04,32.75,31.78,31.65,29.20,28.81,28.66,28.47,25.35,22.83,19.19;HRMS(ESI,positive)m / z calcd for C 49 H 52 N9O7[M-H] -:878.3995; found 878.3932.

[0227] Embodiment 25

[0228] In vitro anti-inflammatory activity test of the compounds of the present invention

[0229] Step a: ICR mouse peritoneal macrophage extraction and culture

[0230] Three days before the experiment, each mouse was injected with 5% broth (sodium thioglycolate) (2 mL) every day to obtain more peritoneal macrophages. Cell extraction was performed according to the following steps:

[0231] 1) The mouse was killed, soaked in 75% ethanol for 2-3 minutes, and transferred to a clean bench. The mouse was fixed on the dissection board in supine position, and the abdominal skin was wiped with ethanol. The abdominal skin was cut open with surgical scissors to expose the abdominal muscle layer (be careful not to damage the abdominal muscle layer), and then the abdominal muscle layer was disinfected with ethanol;

[0232] 2) Use a 5mL syringe to extract RPMI1640 medium (5mL) containing 1% double antibody and inject it into the abdominal cavity. Gently shake the mouse body back and forth, then use a syringe to extract the cell suspension and transfer it to a centrifuge tube. Repeat three times;

[0233] 3) The collected cell suspension was diluted to 1×10 3 After centrifugation at rpm for 5 min, the supernatant was discarded, and the cells were blown with RPMI1640 medium (10 mL) containing double antibodies and centrifuged at 1 × 103 rpm for 5 min;

[0234] 4) Use RPMI1640 medium (5 mL) containing 10% fetal bovine serum and 1% double antibody to blow evenly, take the cell suspension (10 μL) and dilute it 10 times to 100 μL, and place it on a cell counting plate for counting;

[0235] 5) Calculate the number of cells required for the experiment, dilute the cell suspension and directly transfer it to a 96-well plate or a 6-well plate, and incubate it in a cell culture incubator at 37°C and 5% CO2 for 12 hours before conducting the experiment.

[0236] Step b: ELISA to detect inflammatory factor content

[0237] In each well of a 6-well plate, 8 × 10 4 2 mL of cell suspension with a concentration of 100 μg / mL was incubated in a cell culture incubator at 37°C and a CO2 concentration of 5% for 12 hours, then the culture medium was aspirated and 2 mL of the prepared compound was added. After another 1 hour of incubation, 1 μL of 0.5 mg / mL LPS solution was added and incubated for another 72 hours. The ELISA method for detecting inflammatory factors TNF-α and IL-6 can be performed according to the method in the ELISA kit manual. The main steps are as follows.

[0238] 1) Preparation of standard: Dilute the standard twice with standard diluent to 8 concentrations with a maximum concentration of 2000 pg / mL;

[0239] 2) Add 100 μL of the prepared standard and sample of each concentration to each well and incubate at 37°C for 1 hour;

[0240] 3) Aspirate the liquid in the wells, add 100 μL of detection antibody to each well except the blank, and incubate at 37°C for 1 h;

[0241] 4) Remove the liquid from the wells by aspirating, add washing solution (the washing solution is diluted 25 times with double distilled water, 200 μL) to each well, let it stand for 2 minutes, remove the liquid by aspirating, repeat 3 times and air dry;

[0242] 5) Except for the blank, add 100 μL of enzyme-labeled reagent to each well and incubate at 37°C for 60 min;

[0243] 6) Remove the liquid from the wells by aspirating, add 200 μL of washing solution to each well, let stand for 2 min, remove the liquid by aspirating, repeat 3 times and air dry;

[0244] 7) Add 90 μL of color developing agent A and B to each well, mix well, incubate at 37°C in the dark for 15 min, and then add 50 μL of stop solution to terminate the reaction;

[0245] 8) Immediately use an ELISA reader to read the OD value of each well at a wavelength of 450 nm. Use ELISACalc software to calculate the concentration of the inflammatory factor measured.

[0246] Using LRRK2-IN-1 as a positive control, the changes in the release of inflammatory factors IL-6 and TNF-α in primary mouse peritoneal macrophages induced by LPS were detected by ELISA kits after 24 hours of exposure to 10 μM compounds P-1 to P-6 and P-9.

[0247] The experimental results are as follows Figure 1 As shown, Figure 1 Schematic diagram of the in vitro anti-inflammatory activity test results of the compounds of the present invention. Figure 1 The upper picture in the figure is a schematic diagram of the changes in the release of the inflammatory factor IL-6. Figure 1The lower picture in the figure is a schematic diagram of the change in the release of the inflammatory factor TNF-α. It can be seen from the figure that, except for compound P-9, the in vitro anti-inflammatory activity of other compounds is significantly reduced compared with the positive drug LRRK2-IN-1, and the compound has a better inhibitory effect on TNF-α than IL-6. Compound P-9 is a DCLK1 protein degradation targeting chimera with a carbon-oxygen heterochain as a linker. The reason why the molecular carbon-oxygen heterochain has better activity may be that the carbon-oxygen heterochain has better lipid solubility.

[0248] Embodiment 26

[0249] Protein degradation experiment of the compounds of the present invention on DCLK1 (Western blot)

[0250] Step a: Extract protein

[0251] 1) Collect cells: discard the culture medium in the 6-well plate or culture dish, wash the cells twice with pre-cooled PBS, add 100 μL of cell lysis buffer (containing 1% protease inhibitor and 1% phosphatase inhibitor), place at 4°C for 30 min, scrape the cells with a cell scraper, collect the cell suspension into a 1.5 mL centrifuge tube, vortex once every 5 min, and repeat twice;

[0252] 2) Centrifugation: Place the cell suspension in a pre-cooled centrifuge at 4°C, 1.2×10 5 Centrifuge at rpm for 15 min;

[0253] 3) Protein denaturation: Aspirate the supernatant after centrifugation, add one-quarter volume of loading buffer, vortex for 1 min, and denature in a 95°C water bath for 20 min.

[0254] Step b: Protein concentration determination (BCA method)

[0255] 4) Prepare BCA working solution: Solution A and Solution B in a ratio of 50:1;

[0256] 5) Add 18 μL of PBS, 2 μL of protein supernatant and 200 μL of BCA working solution to each well of a 96-well plate, place in a microplate reader, shake the plate at 37°C for 5 min, and then incubate for 25 min;

[0257] 6) Measure the OD value at a wavelength of 562 nm, place it in the standard curve, and determine the protein concentration.

[0258] Step c: Electrophoresis

[0259] 1) Glue preparation;

[0260] 2) Sample loading: Place the gel in the electrophoresis tank, add electrophoresis solution, and remove the comb. Add the protein sample to the loading well according to the calculated volume;

[0261] 3) Run the gel at a constant voltage, 100V for 80 minutes.

[0262] Step d: Transfer

[0263] 4) Cut the gel into required fragments and place them on filter paper. Cut a PVDF membrane of appropriate size and activate it in methanol for 5 minutes, then cover it on the gel.

[0264] 5) Place the transfer clip in the transfer tank and apply constant current of 270A for 100 minutes.

[0265] Step e: Antibody incubation

[0266] 1) Blocking: After transfer, wash the PVDF membrane with TBST, place it in 5% BSA, and shake it at room temperature for 2 hours;

[0267] 2) Primary antibody incubation: Wash the membrane with TBST, then place it in the prepared primary antibody and incubate at room temperature for 2 hours (or at 4°C overnight);

[0268] 3) Secondary antibody incubation: After the primary antibody incubation, wash the membrane three times with TBST (5 min each time), then place it in the secondary antibody solution at room temperature in the dark for 2 h.

[0269] Step f: Exposure

[0270] The membrane was washed three times with TBST (5 min each time) in the dark, scanned with a LI-COR Odyssey scanner, and then the protein bands were analyzed using Image J software.

[0271] In the present invention, PROTAC molecules P-1 to P-10 use VHL as the E3 ligase ligand, P-11 to P-19 use pomalidomide as the E3 ligase ligand, and P-20 to P-23 use lenalidomide as the E3 ligase ligand.

[0272] The experimental results are as follows Figure 2 As shown, Figure 2It is a schematic diagram of the degradation activity test results of DCLK1-PROTAC. Among them, A is a schematic diagram of the degradation activity screening results of PROTAC molecules with VHL as the E3 ligase ligand at 10μM; B is a schematic diagram of the time-dependent degradation experiment results of compound 9 at 10μM; C is a schematic diagram of the degradation activity screening results of PROTAC molecules with pomalidomide as the E3 ligase ligand at 10μM; D is a schematic diagram of the dependency degradation experiment results of compound 14. At a single concentration of 10μM, in the DCLK1 protein degradation targeting chimera (compounds P-1~P-6, P-9) with VHL as the E3 ligase ligand, compounds P-1 and P-9 with carbon-oxygen heterochains and fatty chains containing three carbon atoms have certain degradation activity. In the fatty chain compounds P-2~P-6 with 4-8 carbon atoms, the degradation activity gradually weakens with the increase of chain length ( Figure 2 A); The time-dependent experiment of the compound P-9 with the best anti-inflammatory activity showed that the degradation rate of DCLK1 gradually increased with time from 0.5h to 3h after administration, and the degradation effect did not change after 3h ( Figure 2 B), indicating that PROTAC molecules can achieve maximum degradation at 3h, so the subsequent drug action time is 3h; for some DCLK1 protein degradation targeting chimeras with pomalidomide as E3 ligase ligand, a single concentration of 10μM degradation activity screening was performed, and it was found that compounds P-11, P-12 and P-14 had good degradation activity ( Figure 2 C), which correspond to DCLK1 protein degradation targeting chimeras without linker, with 2 carbon atom fat linker and with 5 carbon atom fat linker. By comparing the degradation activities of two different types of E3 ligase ligands, it was found that the PROTAC molecule with CRBN as the E3 ligase ligand had better degradation activity. The compound P-14 with better degradation activity was selected for concentration-dependent degradation experiments. It was found that in the three concentrations of 0.1-10 μM, as the concentration increased, the degradation efficiency decreased. The reason for the analysis may be that the PROTAC molecule produced a HOOK effect at high concentrations, and the specific degradation efficiency needs to be further verified ( Figure 2 (middle D).

[0273] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this patent can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.

Claims

1. A compound or a pharmaceutically acceptable salt thereof, characterized in that: The compound is selected from one of the following structures:

2. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a chimera targeted for DCLK1 protein degradation.

3. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of anti-inflammatory drugs.